Collected Works of Emili Montserrat

Introduction

Dr. Emili Montserrat is most well known for his work on prognostic factors and stem cell transplantation in CLL. In particular, he introduced ZAP-70 as a prognostic surrogate marker for Ig gene mutational status. He was also responsible for our understanding of the growth patterns seen in the bone marrow biopsy histology of CLL patients, he revived the clinical usefulness of the lymphocyte doubling time (LDT) originally described by Galton, and he wrote one of earliest editorials on the usefulness of minimal residual disease (MRD) in CLL.

A set of video clips in which Dr. Montserrat discusses the development of his research may be found in the Oral History archive.

Collected Works

1971

Rozman C, Manresa F, García San Miguel J, Montserrat E. Hepatopatía del cáncer renal. Med Clin (Barc). 1971:57:555-561.

1973

Urbano Márquez A, Montserrat-Costa E, Ribas Mundó M, Rozman C. Thorotrastosis y cirrosis hepática. A propósito de un caso. Med Clin (Barc). 1973;60:98-101.
Montserrat-Costa E, Urbano Márquez A, Zapater J, Rozman C. Fluorosis vínica (periostitis deformans de Soriano). Med Clin (Barc). 1973;60:652-655.

1975

Rozman C, Montserrat Costa E. Nuevas tendencias en el estudio y clasificación de los linfomas malignos. Med Clin (Barc). 1975;64:257-261.
Montserrat-Costa E, Bruguera M. El antígeno Australia en la enfermedad de Hodgkin. Med Clin (Barc). 1975;64:318.

1976

Domingo Clarós A, Umbert P, Montserrat-Costa E. Xantoleucemia (leucemia mielomonocítica infantil con xantomas). Med Clin (Barc). 1976:65:21-23.
Rozman C, Pumarola J, Montserrat-Costa E, Vives J. “Larva migrans visceral”, otra causa de hipereosinofilia. Med Clin (Barc). 1976;66:337-340.
Montserrat-Costa E, Granje MJ, Weissgerber Ch, Teillet F. Antígeno Australia y enfermedad de Hodgkin (carta). Med Clin (Barc). 1976;66:522.
Rozman C, Grañena A, Valls A, Hernández-Nieto L, Montserrat E, Nomdedeu B, Ercilla G, Vives-Puiggrós J, Vives-Corrons JL, Castillo R. Nuestra primera experiencia con el trasplante de medula osea. Med Clin (Barc). 1976;67(9):437-441.
Matamoros N, Montserrat-Costa E, Valls A, Vives Puiggrós J, Rozman C. Síndromes linfoproliferativos con secreción de inmunoglobulina monoclonal. Sangre (Barc). 1976;21(2):287-295.
Montserrat Costa E, Matamoros N, Vives Puiggrós J, Rozman C. Estudio de las poblaciones celulares en la leucemia linfática crónica. Sangre (Barc). 1976;21(3):477-484.
Montserrat-Costa E. In Rozman C. Encuesta sobre los aspectos clínicos de las anemias refractarias. Sangre (Barc). 1976;21(3-B):557.
Vives Corrons JL, Hernández Nieto L, Montserrat-Costa E, Pujades A, Rozman C. Actividad de las enzimas eritrocitarias en el curso de las anemias refractarias. Sangre (Barc). 1976;21(3-B):647-655.
Vives Corrons JL, Montserrat-Costa E, Pujades A, Woessner S, Rozman C. Déficit congénito de pirimidina 5′ nucleotidasa eritrocitaria: un nuevo tipo de eritroenzimopatía con hemólisis. Sangre (Barc). 1976;21(4):827-835.
Vives-Corrons JL, Montserrat-Costa E, Rozman C. Hereditary hemolytic anemia with erythrocyte pyrimidine 5′-nucleotidase deficiency in Spain. Hum Genet. 1976 Jan;34(3):285-292.

1977

Hernández Nieto L, Montserrat-Costa E, Muncunill J, Rozman C. Bone marrow patterns and clinical staging in chronic lymphocytic leukaemia. Lancet. 1977;309(8024):1269.
Matutes E, Montserrat E, Urbano A, Nomdedeu, Cardellach F, García M. Alopecia generalizada como manifestación inicial de una enfermedad de Hodgkin. Med Clin (Barc). 1977;68:408-410.
Rozmán C, Grañena A, Woessner S, Brugues R, Montserrat E, Hernández-Nieto L, Vives-Corrons JL. Sideroblastosis «en anillo» transitoria en un trasplante medular alogénico. Sangre (Barc). 1977;22(4):508-14.
Montserrat-Costa E. Algunas aportaciones de la inmunología al estudio de los síndromes linfoproliferativos. Sangre (Barc). 1977;22(5-B):716-734.
Hernández-Nieto L, Montserrat-Costa E, Muncunill J, Brugés R, Grañena A, Nomdedeu B, Feliu E y Rozman C. Leucemia linfática crónica: tipos de patrón histopatológico medular y su relación con los estadios clínicos. Sangre (Barc). 1977;22(5-B):882-889.
Montserrat-Costa E, Morey M, Rozman C, Feliu E, Grañena A, Hernandez-Nieto L, Nomdedeu B. Interés de la clasificación por estadios de la leucemia linfoide crónica. Sangre (Barc). 1977;22(5-B):901-911.
Montserrat-Costa E, Matutes E, Rozman C, Feliu E, Grañena A, Hernández-Nieto L, Nomdedeu B, Urbano A. Infecciones en la leucemia linfática crónica. Sangre (Barc). 1977;22(6):968-975.

1978

Hernández-Nieto L, Piera Peña C, Rozman C, Setoain J, Grañena A, Herranz R, Montserrat E, Martín Comín J, Feliu E. Doble gammagrafía medular como método de estudio de las insuficiencias hematopoyéticas. Estudio comparativo con el mielograma, la biopsia medular y la ferrocinética. Med Clin (Barc). 1978;71:117-123.
García San Miguel J, Rozman C, Valls A, Grañena A, Hernández-Nieto L, Montserrat Costa E, Nomdedeu B. Frecuencia de las infecciones en la enfermedad de Hodgkin con y sin esplenectomía. Med Clin (Barc). 1978;71:157-161.
Bueno Aribayos J, Hernández-Nieto L, Aranalde JM, Feliu E, Grañena A, Montserrat E, Nomdedeu B, Rozmán C. Afectación de la medula ósea en los linfomas no hodgkinianos. Sangre (Barc). 1978;23(2):129-37.
Grañena A, Aranalde JM, Feliu E, Muncunill J, Montserrat E, Hernandez Nieto L, Rozman C. Eficacia de las transfusiones de granulocitos en el tratamiento de infecciones graves de pacientes granulocitopénicos. Estudio controlado. Sangre (Barc). 1978;23(3):291-7.
Hernández-Nieto L, Muncunill J, Rozman C, Fabregues M, Feliu E, Grañena A, Montserrat-Costa E, Nomdedeu B. Mielofibrosis y/u osteoesclerosis secundarias. Análisis de cuatrocientas biopsias. Sangre (Barc). 1978;23:402-410.
Rozman C, Grañena A, Nomdedeu B, Vives-Corrons JL, Montserrat E, Hernandez-Nieto L, Feliu E. Attempt of isogeneic bone marrow transplantation without conditioning in a preleukaemic syndrome, negative result [proceedings]. Pathol Biol (Paris). 1978 Jan;26(1):47.

1979

Rozman C, Woessner S, Montserrat E. Leucemia linfoide crónica (tipo B): relación entre el tamaño linfocitario y el estadio clínico. Sangre (Barc). 1979;24(2):166-73.
Bladé J, Montserrat-Costa E, Rozman C, Feliu E, Grañena A, Marín P. Macroglobulinemia con afectación pleural: descripción de un caso y revisión de la literatura. Sangre (Barc). 1979;24(4):467-473.
Cervantes F, Montserrat-Costa E, Rozman C, Aguilar JL, Feliu E, Grañena A, Aranalde JM, Marín P, Vives Corrons JL. Hemoglobinuria paroxística nocturna. Estudio de veintiún casos y revisión de la literatura. Sangre (Barc). 1979;24(5):534-544.
Feliu E, Cardellach F, Matutes E, Vives Corrons JL, Grañena A, Montserrat-Costa E, Brugués R, Rozman C. Aspectos fisiológicos del granulocito neutrófilo humano con especial referencia al quimiotactismo y a la fagocitosis. Sangre (Barc). 1979;24(5-B):656-668.
Cardellach F, Feliu E, Matutes E, Martí M, Vives Corrons JL, Jou JM, Montserrat-Costa E, Grañena A, Brugués R, Rozman C. Exploración de la capacidad de desplazamiento de los granulocitos humanos. Método en soporte de agarosa. Sangre (Barc). 1979;24(5-B):730-738.
Grañena A, Rozman C, Aranalde JM, Feliu E, García J, Marín P, Montserrat-Costa E, Ribás Mundó M, Matutes E. Profilaxis de las infecciones en los pacientes granulopénicos. Sangre (Barc). 1979;24(5-B):857-867.
Cervantes F, Vives Corrons JL, Rozman C, Aguilar JL, Montserrat-Costa E, Feliu E, Grañena A. Actividad de la acetilcolinesterasa eritrocitaria en la hemoglobinuria paroxística nocturna y su relación con la actividad clinicobiológica de la enfermedad. Sangre (Barc). 1979;24(6):1061-1067.
Hernández-Nieto L, Morey M, Grañena A, Montserrat-Costa E, Feliu E, Rozman C. Les nodules lymphoïdes de la moelle dans la splénomegalie myéloide: comparaison avec la leucémie myéloïde chronique. Nouvelle Revue Française d’Hématologie. 1979;21:251-256.
Rozman C, Montserrat Costa E, Morey M, Aranalde JM, Feliu E, Grañena A, Hernández-Nieto L, Nomdedeu B. Sobrevivencia en la leucemia linfoide crónica en relación con los estadios clínicos. Análisis estadístico de 95 casos. Med Clin (Barc). 1979;72:265-273.
Montserrat E, Rozman C. Subclassification of stage II chronic lymphocytic leukaemia with prognostic and therapeutic implications. Lancet. 1979 Oct 20;2(8147):854.
Cervantes F, Montserrat E, Rozman C. Eosinophilic meningitis in Hodgkin’s disease. Ann Intern Med. 1979 Dec;91(6):930.

1980

Diumenjó MC, Montserrat E. Osteonecrosis aséptica en la enfermedad de Hodgkin (carta). Sangre (Barc). 1980;25(4):515.
García López J, Diumenjo MC, Argüelles MV, Marín P, Grañena A, Montserrat E, Rozman C. Tratamiento de los linfomas resistentes a la quimioterapia con la asociación CCNU-Bleomicina-Vincristina (Vinblastina). Sangre (Barc). 1980;25(6):1014-21.
Rozman C, Montserrat E, Feliu E, Woessner S. Lymphocyte size and survival of patients with chronic lymphocytic leukaemia (B-type). Scand J Haematol. 1980 Apr;24(4):315-20.
Cervantes F, Montserrat E, Rozman C, Diumenjo C, Feliu E, Grañena A. Low-dose vincristine in the treatment of corticosteroid-refractory idiopathic thrombocytopenic purpura (ITP) in non-splenectomized patients. Postgrad Med J. 1980 Oct;56(660):711-4.
Montserrat E, Cervantes F, Marin P, Matutes E, Vives-Corrons JL, Grañena A, Rozman C. Síndrome aplasia-hemoglobinuria paroxística nocturna. Estudio comparativo clínico y biológico con la enfermedad hemoglobinuria paroxística nocturna. Med Clin (Barc). 1980 Nov 25;75(9):369-72.

1981

Cervantes F, Rozman C, Ballesta F, Brugues R, Grañena A, Montserrat E, Nomdedeu B. Crisis blástica simulando leucemia aguda como manifestación inicial de la leucemia mieloide crónica. Estudio de tres casos. Sangre (Barc). 1981;26(1):96-103.
Feliu E, Rozman C, Matutes E, Montserrat E, Woessner S, Berga L, Cardellach F, Brugues RM, Jou JM, Vives Corrons JL. Sobre la capacidad fagocítica de los tricoleucocitos. Sangre (Barc). 1981;26(2):145-58.
Cardellach F, Llebaría C, Sierra J, Quesada E, Montserrat E, Ingelmo M, Balcells Gorina A. «Linfoma de Lennert». Estudio clínico-patológico de un caso. Sangre (Barc). 1981;26(2):203-8.
Montserrat E, Curiá MD, Carreras E, Vives Corrons JL, Rozman C. Células de Reed-Sternberg en el líquido pleural de una enfermedad de Hodgkin (carta). Sangre (Barc). 1981;26(3):401-403.
Rozman C, Grañena A, Marín P, Nomdedeu B, Montserrat E, Feliu E, Puig L, Blade J, Cervantes F, Brugués R, Vives-Corrons JL, Ercilla G, Vives-Puiggrós J, Gelabert A, Castillo R. Trasplante medular alogénico en aplasia medular grave. Análisis de 12 casos consecutivos. Sangre (Barc). 1981;26(4):456-62.
Montserrat E, Lafuente R, Ribalta T, Woessner S, Rozman C. Leucemia de células linfosarcomatosas B (tipo centroblástico) con actividad fosfatasa ácida (isoenzima 5) sensible al tartrato. Sangre (Barc). 1981;26(4):504-7.
Grañena A, Rozman C, Hernández Prieto M, Lizuain MC, Feliu E, Montserrat E, García J, Marín P, Nomdedeu B, Cervantes F, Blade J, Carreras E, Diumenjo MC, Vives-Corrons JL, Vives Puiggros J, Castillo R. Trasplante de medula ósea en la leucemia aguda. Sangre (Barc). 1981;26(5B):901-18.
Bladé J, Montserrat E, Bruguera M, Aranalde J, Grañena A, Cervantes F, Rozman C. Multiple myeloma in primary biliary cirrhosis. Scand J Haematol. 1981 Jan;26(1):14-8.
Estrach T, Lecha M, Mascaró M, Montserrat E, Rozman C. Cutaneous T-cell lymphomas (letter). Ann Intern Med. 1981 Mar 1;94(3):413.
Rozman C, Hernandez-Nieto L, Montserrat E, Brugues R. Prognostic significance of bone-marrow patterns in chronic lymphocytic leukaemia. Br J Haematol. 1981 Apr;47(4):529-37.
Rozman C, Marin P, Grañena A, Nomdedeu B, Montserrat E, Feliu E, Vives-Corrons JL. Prognosis in acquired aplastic anaemia. A multivariate statistical analysis of 80 cases. Scand J Haematol. 1981 Apr;26(4):321-9.
Binet JL, Catovsky D, Chandra P, Dighiero G, Montserrat E, Rai KR, Sawitsky A. Chronic lymphocytic leukaemia: Proposals for a revised prognostic staging system. Br J Haematol. 1981 Jul;48(3):365-367.
Feliu E, Woessner S, Matutes E, Cardellach F, Grañena A, Marin P, Puig L, Vives-Corrons JL, Montserrat E, Rozman C. Comparative morphology of granulocytes collected by three methods of leukapheresis. A light microscopy and transmission electron microscopy study. Transfusion. 1981 Sep-Oct;21(5):517-26.
Cervantes F, Montserrat E, Rozman C. Treatment of idiopathic thrombocytopenic purpura. N Engl J Med. 1981 Oct 1;305(14):830.
Estruch R, Rozman C, Urbano-Márquez A, Montserrat E, Grau JM, Feliu E, Berga L, Brugués R, Vives-Corrons JL. Leucemia prolinfocítica de células T. Estudio citomorfológico, citoquímico y ultrastructural cuantitativo. Med Clin (Barc). 1981 Nov 10;77(8):311-7.

1982

Miró JM, Gatell JM, Llebaria C, Montserrat E, Garcia SanMiguel J. Hodgkin’s disease associated with unusual immunological manifestations. Nouv Rev Fr Hematol. 1982;24(2):81-3.
Montserrat E. Síndromes limfoproliferatives cròniques: noves estratègies en el pronòstic y tractament. An Med (Barc). 1982; LXVIII: 964.
Montserrat E, Nomdedeu B, Diumenjó C, Estrach MT, Rozman C. Neoplasm associated with hairy-cell leukemia. A case report. Acta Haematol. 1982;67(2):141.
Cervantes F, Ribera JM, Grañena A, Montserrat E, Rozman C. Tumour lysis syndrome with hypocalcaemia in accelerated chronic granulocytic leukaemia. Acta Haematol. 1982;68(2):157-9.
Montserrat E, Brugués RM, Vives Corrons JL, Rozman C. Bone-marrow necrosis in chronic lymphocytic leukaemia. Clin Lab Haematol. 1982;4(1):94.
Montserrat E, Marques-Pereira JP, Rozman C, Ballesta AM, Aguilar JL, Elena M. Serum beta-2 microglobulin in chronic lymphocytic leukaemia. Clin Lab Haematol. 1982;4(3):323-5.
Nomdedeu B, Ribera Santasusana JM, Sánchez Bisonó J, Montserrat E, Rozman C. Purpura trombopenica megacariotica por metoclopramida. Sangre (Barc). 1982;27(1):97-8.
Marques-Pereira JP, Montserrat E, Rozman C, Ballesta AM, Aguilar JL, Elena M. Beta-2 microglobulina sérica en la leucemia linfática crónica en relación con los estadios clínicos. Sangre (Barc). 1982;27(5):891-8.
Mascaro JM, Montserrat E, Estrach T, Feliu E, Ferrando J, Castel T, Mallolas J, Rozman C. Specific cutaneous manifestations of Waldenström’s macroglobulinaemia. A report of two cases. Br J Dermatol. 1982 Feb;106(2):217-22.
Rozman C, Montserrat E, Felíu E, Grañena A, Marín P, Nomdedeu B, Vives Corrons JL. Prognosis of chronic lymphocytic leukemia: a multivariate survival analysis of 150 cases. Blood. 1982 May;59(5):1001-5.
Blade J, Rozman C, Grañena A, Montserrat E. Aggressive terminal phase of multiple myeloma. Arch Intern Med. 1982 Sep;142(9):1755-6.

1983

Diumenjó MC, Bladé J, Montserrat E. Los linfomas malignos. Medicina Integral. 1983; 4: 52.
Ribera JM, Montserrat E, Rozman C. Cardiotoxicidad de los antraciclínicos: Revisión. Sangre (Barc). 1983;28(1):54-68.
Cervantes F, Rozman C, Ballesta F, Bladé J, Brugués R, Feliu E, Grañena A, Marín P, Montserrat E, Nomdedeu B, Salguero R. Leucemia mieloide crónica. Descripción de una serie de 207 casos. Sangre (Barc). 1983;28(2):140-50.
Feliu E, Rozman C, Berga L, Vives Corrons JL, Montserrat E. Apliación de la microscopía electrónica de transmisión en el diagnóstico de los síndromes linfoproliferativos crónicos de expresión leucémica. Biología y Clínica Hematológica. 1983;5:195-208.
Montserrat E, Rozman C. Bone marrow biopsy in chronic lymphocytic leukaemia: a study of 208 cases. Haematologia (Budap). 1983;16(1-4):73-9.
Vives Corrons JL, Pujades A, Aguilar i Bascompte JL, Montserrat E. Electrophoretic and kinetic studies of a new mutant red cell pyrimidine 5′-nucleotidase. Enzyme. 1983;30(3):149-54.
Bladé J, Gastón F, Montserrat E, Marín P, Grañena A, Bachs A, Rozman C. Spinal subarachnoid hematoma after lumbar puncture causing reversible paraplegia in acute leukemia. Case report. J Neurosurg. 1983 Mar;58(3):438-9.
Bladé J, Gastón F, Montserrat E, Grañena A, Rozman C. Paraplejia reversible debida a un hematoma subaracnoideo espinal tras punción lumbar en un paciente trombocitopénico. Med Clin (Barc). 1983 Mar 5;80(7):342.
Bladé J, Montserrat E, Rozman C. Peculiaridades clínicas y evolutivas del mieloma de cadenas ligeras. Med Clin (Barc). 1983 Apr 9;80(12):560-1.
Montserrat E. Leucemia linfática crónica/1983. Med Clin (Barc). 1983;80:711-715.
Montserrat E, Estruch R, Urbano-Márquez A, Grau JM, Ribera JM, Rozman C. Linfadenopatía inmunoblástica: estudio de 12 casos. Med Clin (Barc). 1983 May 21;80(18):775-9.
Bladé J, Feliú E, Rozman C, Estapé J, Millá A, Montserrat E. Cross-resistance to alkylating agents in multiple myeloma. Cancer. 1983 Sep 1;52(5):786-9.
Casademont J, Sala M, Grau JM, Estruch R, Montserrat E, Urbano-Márquez A, Rozman C. Afección pleural en la leucemia linfática crónica: a propósito de dos observaciones. Med Clin (Barc). 1983 Sep 10;81(6):261-2.
Ribera JM, Ferrer O, Bladé J, Valls V, Carreras E, Grañena A, Montserrat E, Rozman C. Endocarditis por Aspergillus en un paciente con leucemia aguda linfoblástica en remisión. Med Clin (Barc). 1983 Oct 8;81(10):436-9.
Feliu E, Rozman C, Montserrat E, Gallart T, Marques-Pereira J. Cytoplasmic inclusions in lymphocytes of chronic lymphocytic leukaemia. Scand J Haematol. 1983 Nov;31(5):510-2.

1984

Bordas X, Gratacos R, Castel T, Cervantes F, Montserrat E, Mascaró JM. Sarcoma inmunoblástico asociado a dermatitis herpetiforme. Med Cutan Ibero Lat Am. 1984;12(3):239-43.
Rodríguez Fernández JM, Montserrat E, Rozman C, Rios A, Vallespí MT, González Aza C, Alcalá A, Gutiérrez M, Morey M, Brugués R. Sequential bone marrow biopsy in chronic lymphocytic leukaemia. Bibl Haematol. 1984;(50):81-6.
Montserrat E, Rozman C. Combination chemotherapy in chronic lymphocytic leukemia: a brief review. Nouv Rev Fr Hematol. 1984;26:87-89.
Rozman C, Montserrat E, Rodríguez Fernández JM, Ayats R, Vallespí T, Parody R, Ríos A, Prados D, Morey M, Gomis F, Alcala A, Gutierrez M, Maldonado J, Gonzalez C, Giralt M, Hernandez Nieto L, Cabrera A, Ferandez-Rañada JM, Brugues R. ¿La leucemia linfática crónica, acorta la vida? Sangre (Barc). 1984;29(2):156-63.
Cervantes F, Rozman C, Ballesta F, Bladé J, Feliú E, Grañena A, Mariń P, Montserrat E, Nomdedeu B, Vives Corrons JL. Expresión clínico-biológica de la leucemia granulocítica crónica en fase diagnóstica y su significado pronóstico. Sangre (Barc). 1984;29(4-B):504-20.
Rozman C, Montserrat E, Rodríguez Fernández JM, Ayats R, Vallespí T, Parody R, Ríos A, Prados D, Morey M, Gomis F, Alcala A, Gutierrez M, Maldonado J, Gonzalez C, Giralt M, Hernandez Nieto L, Cabrera A, Fernandez-Rañada JM, Brugues R. Biopsia medular en la leucemia linfática crónica y sus correlaciones clínico-hematológicas. Sangre (Barc). 1984;29(6):1008-17.
Pedro-Botet Montoya J, Montserrat E, Cot Martínez X, Urbano-Márquez A. Shock anafilactico tras la inyeccion subcutanea de “blue patent violet” en el curso de linfografias. Sangre (Barc). 1984;29(6):1053-4.
Bladé J, Rozman C, Montserrat E, Grañena A, Brugués R, Cervantes F, Feliu E, Marín P, Nomdedeu B, Vives-Corrons JL. Mieloma múltiple: descripción de una serie de 170 casos. Med Clin (Barc). 1984 Feb 25;82(7):287-94.
Sierra J, Llebaría C, Prat J, Cervantes F, Montserrat E, Rozman C. Adenocarcinoma gástrico asociado a una enfermedad de Hodgkin con infiltración amigdalar y de la serosa gástrica. Med Clin (Barc). 1984 Apr 28;82(16):719-22.
Montserrat E, Marques-Pereira JP, Gallart MT, Rozman C. Bone marrow histopathologic patterns and immunologic findings in B-chronic lymphocytic leukemia. Cancer. 1984 Aug 1;54(3):447-51.
Rozman C, Montserrat E, Rodríguez-Fernández JM, Ayats R, Vallespí T, Parody R, Ríos A, Prados D, Morey M, Gomis F, Alcalá A, Gutiérrez M, Maldonado J, González C, Giralt M, Hernández-Nieto L, Cabrera A, Fernández-Rañada JM. Bone marrow histologic pattern–the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood. 1984 Sep;64(3):642-8.
Bladé J, Rozman C, Montserrat E, Grañena A. Impact of renal function on the myeloma staging. Scand J Haematol. 1984 Oct;33(4):399-400.
Montserrat E, Carreras E, Rozman C, Olivé T, Bladé J, Cervantes F, Feliu E, Gardella S, Grañena A, Marín P, Nomdedeu B. Tratamiento de la enfermedad de Hodgkin con ABVD. Med Clin (Barc). 1984 Dec 1;83(18):739-41.

1985

Gardella S, Montserrat E, Rozman C, Llebaría C, Diumenjó MC, Olivé T, Bladé J, Cervantes F, Feliu E, Grañena A, Marín P, Nomdedeu B, Brugués R. Linfomas no hodgkinianos de histología “favorable”: Respuesta al tratamiento y supervivencia. Neoplasia. 1985; 2: 149-153.
Sierra J, Marín P, Cararach V, Nomdedeu B, Grañena A, Montserrat E, Rozman C. Asociación de aplasia medular y embarazo: nuevas observaciones. Med Clin (Barc). 1985 Jan 19;84(2):65-7.
Rozman C, Grañena A, Marín P, Hernández-Prieto M, Nomdedeu B, Montserrat E, Feliu E, Bladé J, Cervantes F, Vives Corrons JL, Vives Puiggrós J, Castillo R. Trasplante medular alogénico en aplasia medular grave. Factores determinantes del resultado en una serie de 27 casos consecutivos. Med Clin (Barc). 1985 Feb 2;84(4):129-34.
Xaubet A, Diumenjo MC, Maŕin A, Montserrat E, Estopá R, Llebaría C, Austí A, Rozman C. Characteristics and prognostic value of pleural effusions in non-Hodgkin’s lymphomas. Eur J Respir Dis. 1985 Feb;66(2):135-40.
Urbano-Márquez A, Estruch R, Fernandez-Huerta JM, Montserrat E, Rozman C. Etoposide in the treatment of multifocal eosinophilic granuloma. Cancer Treat Rep. 1985 Feb;69(2):238-9.
Cervantes F, Rozman C, Bladé J, Montserrat E, Grañena A. Treatment of blast crisis of chronic myelogenous leukemia with vincristine, prednisone, and cytarabine. Cancer Treat Rep. 1985 Jul-Aug;69(7-8):923-4.
Grañena A, Rozman C, Carreras E, Marín P, Hernández-Prieto M, Olivé MT, Nomdedeu B, Montserrat E, Feliu E, Bladé J, Cervantes F, Vives Corrons JL, Vives Puiggrós J, Castillo R. Trasplante de medula ósea en la leucemia aguda: resultados en una serie de 51 pacientes consecutivos preparados con ciclofosfamida e irradiación corporal total. Med Clin (Barc). 1985 Oct 19;85(12):479-85.
Rozman C, Montserrat E, Rodríguez Fernández JM, Ayats R, Vallespí T, Parody R, Ríos A, Prados D, Morey M, Gomis F, Alcalá A, Gutiérrez M, Maldonado J, González C, Giralt M, Hernández Nieto L, Cabrera A, Fernández-Rañada JM, Brugués R. Pronóstico de la leucemia linfática crónica: ¿estadios clínicos o histopatología medular?. Med Clin (Barc). 1985 Oct 26;85(13):521-4.
Montserrat E, Alcalá A, Parody R, Domingo A, García-Conde J, Bueno J, Ferrán C, Sanz MA, Giralt M, Rubio D, Antón I, Estapé J, Rozman C. Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer. 1985 Nov 15;56(10):2369-75.
Reverter JC, Viñolas N, Montserrat E, Rozman C. Hodgkin’s disease in external mammary lymph nodes. Ann Intern Med. 1985 Dec;103(6 Pt 1):964.

1986

Feliu E, Cervantes F, Montserrat E, Rozman C. Leucemias crónicas (I). Medicina Integral. 1986; 8: 365-372.
Feliu E, Cervantes F, Montserrat E, Rozman C. Leucemias crónicas (II). Medicina Integral. 1986; 8: 411-418.
Giralt M, Montserrat E, Maldonado J, Rodríguez-Fernández JM, Cirera L, Mayans JR, Zubizarreta A, Guzmán MC, Estapé J. Terapéutica de los linfomas no hodgkinianos clínicamente agresivos en estadios III y IV con CHOP. Estudio del grupo PETHEMA. Neoplasia. 1986; 3: 119-124.
Grañena A, Gardella S, Marín P, Carreras E, Montserrat E, Rozman C. Eficacia del 2-mercaptoetanol sulfonato sódico (mesnum) en la profilaxis de la cistitis hemorrágica en pacientes sometidos a trasplante de medula ósea. Sangre (Barc). 1986;31(3):307-10.
Pedro-Botet Montoya J, Montserrat E, Diumenjó MC, Olivé T, Llebaría C, Grau JM, Urbano-Márquez A, Rozman C. Afectación del sistema nervioso central en los linfomas no hodgkinianos. Sangre (Barc). 1986;31(3):329-34.
Pereira A, Montserrat E, Nomdedeu B, Urbano Ispizua A, Rozman C. Recidivas tardías en los linfomas no hodgkinianos con histología desfavorable. Sangre (Barc). 1986;31(5):582-6.
Cervantes F, Rozman C, Nomdedeu B, Blade J, Montserrat E. Leucemia mieloide crónica: comparación de la monoterapia con busulfán frente a busulfán y ciclos de vincristina y 6-mercaptopurina. Rev Clin Esp. 1986 Jan;178(1):4-7.
Gardella S, Nomdedeu B, Peyrí E, Bombí JA, Montserrat E, Rozman C. Tumor prostático como forma de presentación de un linfoma indiferenciado tipo Burkitt. Med Clin (Barc). 1986 Mar 22;86(11):466-8.
Montserrat E, Sanchez-Bisono J, Viñolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol. 1986 Mar;62(3):567-75.
Pedro-Botet J, Estruch R, Montserrat E, Urbano-Márquez A, Rozman C. Thrombocytopenic purpura as first manifestation of an inapparent Hodgkin’s disease. Scand J Haematol. 1986 Apr;36(4):408-10.
Cervantes F, Reverter JC, Montserrat E, Rozman C. Treatment of advanced resistant Hodgkin’s disease with lomustine, etoposide, and prednimustine. Cancer Treat Rep. 1986 May;70(5):665-7.
Montserrat E, Rozman C. Laparotomía exploradora en la enfermedad de Hodgkin: ¿una exploración sistemática o excepcional? Med Clin (Barc). 1986 May 17;86(19):802-4.
Bladé J, Rozman C, Montserrat E. Long-term survival in multiple myeloma. Arch Intern Med. 1986 Aug;146(8):1637-8.
Bladé J, Rozman C, Montserrat E, Cervantes F, Feliu E, Grañena A, Marín P, Nomdedeu B. Treatment of alkylating resistant multiple myeloma with vincristine, BCNU, doxorubicin and prednisone (VBAP). Eur J Cancer Clin Oncol. 1986 Oct;22(10):1193-7.
Pereira A, Montserrat E, Cervantes F, Rozman C. Advanced lymphoma and CHOP chemotherapy. Ann Intern Med. 1986 Oct;105(4):631.

1987

Montserrat E, Rozman C. Clinicopathologic staging in chronic lymphocytic leukemia. In: Rai KR, Gale RP, eds. Chronic Lymphocytic Leukemia: Recent Progress and Future Direction. UCLA Symposium on Molecular and Cellular Biology, New Series, vol. 59. New York, NY: Alan R. Liss, Inc.; 1987: 215-224.
Montserrat E. Modificadores de la respuesta biológica: pasado, presente y futuro. Biología y Clínica Hematológica. 1987; 9: 127-130.
Montserrat E, Rozman C. Bone marrow biopsy in chronic lymphocytic leukemia: a review of its prognostic importance. Blood Cells. 1987;12(2):315-26.
Viñolas N, Reverter JC, Urbano-Ispizua A, Montserrat E, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukemia: an update of its prognostic significance. Blood Cells. 1987;12(2):457-70.
Ribera JM, Viñolas N, Urbano-Ispizua A, Gallart T, Montserrat E, Rozman C. “Spontaneous” complete remissions in chronic lymphocytic leukemia: report of three cases and review of the literature. Blood Cells. 1987;12(2):471-83.
Pereira A, Bladé J, Ribera JM, Sierra J, Llebaria C, Nomdedeu B, Montserrat E, Rozman C. Historia natural de los linfomas no hodgkinianos de histología “favorable” en estudio avanzado. Sangre (Barc). 1987;32(2):202-10.
Urbano Ispizua A, Montserrat E, Rozman C, Feliu E, Vives-Corrons JL. Estudio inmunoenzimático de la sangre periférica y de la medula ósea en la leucemia linfática crónica. Sangre (Barc). 1987;32(6):707-14.
Urbano Ispizua A, Ribera JM, Bladé J, Marín P, Rives A, Feliu E, Letang E, Nomdedeu B, Grañena A, Montserrat E, Rozman C. Aplasia medular grave asociada a timoma. Presentación de dos casos y revisión de la literatura. Med Clin (Barc). 1987 Jan 24;88(3):110-3.
Pereira A, Cervantes F, Montserrat E, Llebaria C, Rozman C. Non-Hodgkin’s lymphoma of unfavourable histology: a multivariate analysis of factors predicting the response to CHOP. Hematol Oncol. 1987 Jul-Sep;5(3):203-11.
Rai KR, Montserrat E. Prognostic factors in chronic lymphocytic leukemia. Semin Hematol. 1987 Oct;24(4):252-6.
Rozman C, Marín P, Nomdedeu B, Montserrat E. Criteria for severe aplastic anaemia. Lancet. 1987 Oct 24;2(8565):955-7.

1988

Rozman C, Montserrat E. Bone marrow biopsy in chronic lymphocytic leukemia. In: Polliack A, Catovsky D, eds. Chronic Lymphocytic Leukemia. Chur, Switzerland: Harwood Academic Publishers; 1988: 183-191.
Cervantes F, Montserrat E. Tratamiento actual de las leucemias crónicas. JANO. 1988;824:47-57.
Monforte R, Feliu E, Campo E, Llebaria C, Montserrat E, Vives-Corrons JL, Rozman C. Intestinal lymphoma in a patient with chronic lymphocytic leukemia of atypical phenotype: Richter’s syndrome of unusual presentation. Acta Haematol. 1988;80(2):116-9.
Rozman C, Montserrat E. Advances in therapy of chronic lymphocytic leukaemia. Haematologia (Budap). 1988;21(1):17-23.
Urbano-Ispizua A, Montserrat E, Martí A, Feliu E, Vives-Corrons JL, Rozman C. Immunohistochemical study of bone marrow sections in CLL. Nouv Rev Fr Hematol. 1988;30(5-6):325-6.
Montserrat E, Viñolas N, Reverter JC, Rozman C. Natural history of chronic lymphocytic leukemia: on the progression and progression and prognosis of early clinical stages. Nouv Rev Fr Hematol. 1988;30(5-6):359-61.
Rozman C, Montserrat E. Bone marrow biopsy in chronic lymphocytic leukemia. Nouv Rev Fr Hematol. 1988;30(5-6):369-71.
Montserrat E, Alcalá A, Alonso C, Besalduch J, Moraleda JM, García-Conde J, Gutierrez M, Gomis F, Garijo J, Guzmán MC, Estapé J, Rozman C. A randomized trial comparing chlorambucil plus prednisone vs cyclophosphamide, melphalan, and prednisone in the treatment of chronic lymphocytic leukemia stages B and C. Nouv Rev Fr Hematol. 1988;30(5-6):429-32.
Rozman C, Montserrat E. Critical factors in new therapeutic approaches in chronic lymphocytic leukaemia (CLL). Nouv Rev Fr Hematol. 1988;30(5-6):453-5.
Rozman C, Montserrat E, Viñolas N. Serum immunoglobulins in B-chronic lymphocytic leukemia. Natural history and prognostic significance. Cancer. 1988 Jan 15;61(2):279-83.
Vives Corrons JL, Rozman C, Pujades MA, Colomer D, Perez Vila E, Anegon I, Gallart T, Vives Puiggrós J, Viñolas N, Montserrat E. Combined assay of adenosine deaminase, purine nucleoside phosphorylase, and lactate dehydrogenase in the early clinical evaluation of B-chronic lymphocytic leukemia. Am J Hematol. 1988 Mar;27(3):157-62.
Montserrat E, Boccia A, Feliu E, Urbano-Ispizua A, Campo E, Brugués R, Rozman C. Tricoleucemia: Análisis de 11 casos. Sangre (Barc). 1988 Apr;33(2):108-13.
Rozman C, Montserrat E, Viñolas N, Urbano-Ispizua A, Ribera JM, Gallart T, Compernolle C. Recombinant alpha 2-interferon in the treatment of B chronic lymphocytic leukemia in early stages. Blood. 1988 May;71(5):1295-8.
Cervantes F, Reverter JC, Bladé J, Montserrat E, Rozman C. Tratamiento con CEP (CCNU, VP-16 y prednimustina) de la enfermedad de Hodgkin resistente a CVPP y ABVD. Resultados en 21 pacientes. Sangre (Barc). 1988 Jun;33(3):184-7.
Pereira A, Montserrat E. Linfomas no hodgkinianos: interés de los factores pronósticos en las decisiones terapéuticas. Med Clin (Barc). 1988 Jun 25;91(5):172-4.
López Guillermo A, Pereira A, Montserrat E, Rozman C. Esplenectomía en la leucemia linfática crónica. Sangre (Barc). 1988 Aug;33(4):287-90.
Bladé J, Rozman C, Reverter JC, Montserrat E. Factores pronósticos en el myeloma múltiple. Rev Clin Esp. 1988 Sep;183(4):215.
Bladé J, Montserrat E. ¿Qué hacer ante una enfermedad de Hodgkin resistente o en recaída? Med Clin (Barc). 1988 Oct 8;91(11):413-5.
Reverter JC, Sierra J, Martí-Tutusaus JM, Montserrat E, Grañena A, Rozman C. Hypocholesterolemia in acute myelogenous leukemia. Eur J Haematol. 1988 Oct;41(4):317-20.

1989

Gale RP, Binet JL, Catovsky D, Dighiero G, Montserrat E, Rai KR, Rozman C, Sawitsky A. 4th International Workshop on CLL. Leuk Res. 1989;13(6):505-510.
López Guillermo A, Cervantes F, Bladé J, Matutes E, Urbano A, Montserrat E, Rozman C. Central nervous system involvement demonstrated by immunological study in prolymphocytic variant of chronic lymphocytic leukemia. Acta Haematol. 1989;81(2):109-11.
Montserrat E, Lozano M, Urbano-Ispizua A, Matutes E, Feliu E, Ercilla G, Vives-Corrons JL, Rozman C. Adult T-cell Leukemia in a Chilean Resident in Spain: Long-Lasting Remission after 2-Deoxycoformycin Treatment. Leuk Lymphoma. 1989;1(1):47-9.
Rozman M, Montserrat E, Bruguera M, Grau JM, Terés J, Rozman C. Leucemia linfática crónica e hipertensión portal: ¿una asociación causal? Med Clin (Barc). 1989 Jan 14;92(1):26-8.
Rozman C, Montserrat E, Rozman M, Bladé J, Cervantes F. Análisis de la respuesta al tratamiento. Consideraciones sobre las variables pronósticas evolutivas (tiempo-dependientes). Med Clin (Barc). 1989 Jan 21;92(2):52-5.
López Guillermo A, Martí JM, Bladé J, Nomdedeu B, Montserrat E, Rozman C. Leucemia de células plasmáticas. Estudio de diez casos. Sangre (Barc). 1989 Feb;34(1):28-31.
Binet JL, Catovsky D, Dighiero G, Gale RP, Montserrat E, Rai KR, Rozman C, Sawitsky A. Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. Ann Intern Med. 1989 Feb 1;110(3):236-238.
Lozano-Molero M, Ribera JM, Nomdedeu B, Llebaría C, Campo E, Montserrat E, Rozman C. Linfomas malignos (no hodgkinianos y enfermedad de Hodgkin) asociados a la infección por el virus de la inmunodeficiencia humana. Estudio de nueve casos. Med Clin (Barc). 1989 Mar 4;92(8):302-5.
Ribera JM, Cervantes F, Reverter JC, Montserrat E, Rozman C. Acute transformation of chronic myelomonocytic leukaemia: a multivariate study of predictive factors. Eur J Haematol. 1989 Mar;42(3):284-8.
Pereira A, Cervantes F, Montserrat E, Rozman C. Mielofibrosis primaria: descripción de una serie de 53 pacientes. Med Clin (Barc). 1989 Apr 15;92(14):521-5.
Urbano-Ispizua A, Campo E, Feliu E, Quintero L, Vives Corrons JL, Montserrat E, Rozman C. Linfoma no hodgkiniano con reacción granulomatosa esplénica. Med Clin (Barc). 1989 May 6;92(17):661-4.
Bladé J, Rozman C, Cervantes F, Reverter JC, Montserrat E. A new prognostic system for multiple myeloma based on easily available parameters. Br J Haematol. 1989 Aug;72(4):507-11.
López Guillermo A, Sierra J, Montserrat E. Tratamiento de los linfomas no hodgkinianos resistentes o en recaída. Med Clin (Barc). 1989 Sep 23;93(8):304-8.
Marin P, Nomdedeu B, Rovira M, Montserrat E, Rozman C. Cyclosporin A versus antilymphocytic globulin in severe aplastic anaemia. Br J Haematol. 1989 Oct;73(2):285-6.
Binet JL, Catovsky D, Chastang C, Dighiero G, Fooks J, Galton DAG, Gates A, Hamblin TJ, Han T, Hansen MM, Keating MJ, Montserrat E, Pangalis GA, Polliack A, Rai KR, Richards S, International Workshop on CLL. Prognostic features of early chronic lymphocytic leukaemia. Lancet. 1989 Oct 21;334(8669):968-969.
Ribera JM, Urbano-Ispizua A, Matutes E, Campo E, Grañena A, Vives-Corrons JL, Montserrat E, Rozman C. Síndromes linfoproliferativos T agudos. Estudio de 29 casos. Med Clin (Barc). 1989 Oct 28;93(13):481-5.
López-Guillermo A, Reverter JC, Cervantes F, Viñolas N, Rovira M, Urbano-Ispizua A, Montserrat E, Rozman C. Neoplasias asociadas a la leucemia linfática crónica. Incidencia y características en una serie de 232 pacientes. Med Clin (Barc). 1989 Dec 2;93(18):681-3.
Rozman C, Montserrat E. Chronic lymphocytic leukaemia: when and how to treat. Blut. 1989 Dec;59(6):467-74.
Villamor N, Montserrat E, Urbano-Ispízua A, Ribera JM, Rovira M, Vives Corrons JL, Rozman C. Efecto del tratamiento con alfa-interferón recombinante sobre la actividad natural killer en pacientes con leucemia linfática crónica de tipo B. Sangre (Barc). 1989 Dec;34(6):485-8.

1990

Montserrat E, Martí JM, Reverter JC, Rozman C. Efficacy of ABVD Therapy in Resistant Hodgkin’s Disease. Leuk Lymphoma. 1990;1(2):119-22.
Rovira M, Lopez-Guillermo A, Cervantes F, Montserrat E, Rozman C. Scleroderma Associated with Idiopathic Myelofibrosis. Leuk Lymphoma. 1990;1(2):153-5.
Rovira M, Marin P, Martin-Ortega E, Montserrat E, Rozman C. Alternaria infection in a patient receiving chemotherapy for lymphoma. Acta Haematol. 1990;84(2):98-100.
Salgado C, Cervantes F, Creus L, Montserrat E, Rozman C. Neumonía intersticial como complicación del tratamiento con fludarabina en un paciente con leucemia linfática crónica. Neoplasia. 1990;7:192-194.
Ribera JM, Grañena A, Rozman C, Urbano-Ispizua A, Bladé J, Carreras E, Cervantes F, Marín P, Sierra J, Nomdedeu B, Montserrat E. Leucemia aguda linfoblástica del adulto: resultados preliminares del Protocolo LAL-86. Sangre (Barc). 1990;35:26-32.
Bladé J, Urbano A, López Guillermo A, Rozman M, Rovira M, Montserrat E, Rozman C. Tratamiento del mieloma múltiple con vincristina, ciclofosfamida, melfalán y prednisona (VCMP). Resultados a largo plazo en 63 pacientes. Sangre (Barc). 1990 Apr;35(2):93-7.
Cervantes F, Rozman M, Salgado C, Vives-Corrons JL, Montserrat E, Rozman C. Crisis blástica de la leukemia mieloide crónica con cromosoma Filadelfia positive: perfil clinicohematológico y evolutivo en 80 pacientes. Med Clin (Barc). 1990 May 12;94(18):681-4.
Molica S, Reverter JC, Alberti A, Montserrat E. Timing of diagnosis and lymphocyte accumulation patterns in chronic lymphocytic leukemia: analysis of their clinical significance. Eur J Haematol. 1990 May;44(5):277-81.
Urbano-Ispizua A, Matutes E, Villamor N, Ribera JM, Feliu E, Montserrat E, Grañena A, Vives-Corrons JL, Rozman C. Clinical significance of the presence of myeloid associated antigens in acute lymphoblastic leukaemia. Br J Haematol. 1990 Jun;75(2):202-7.
Rozman M, Montserrat E, Cervantes F, Bladé J, Marín P, Rozman C. Tratamiento con ciclosporina A de la anemia asociada a la leucemia linfática crónica. Sangre (Barc). 1990 Aug;35(4):321-5.
Cervantes F, Rozman M, Rosell J, Urbano-Ispizua A, Montserrat E, Rozman C. A study of prognostic factors in blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia. Br J Haematol. 1990 Sep;76(1):27-32.
Marín P, Rovira M, Sanz C, Montserrat E, Rozman C. Efecto de la administración de rhGM-CSF en un paciente con aplasia medular resistente al tratamiento inmunosupresor. Sangre (Barc). 1990 Oct;35(5):397-9.
Cervantes F, Salgado C, Montserrat E, Rozman C. Fludarabine for prolymphocytic leukaemia and risk of interstitial pneumonitis. Lancet. 1990 Nov 3;336(8723):1130.
Escoda L, López-Guillermo A, Formigón M, Estrach T, Cervantes F, Montserrat E, Rozman C. Tratamiento de diferentes síndromes linfoproliferativos con deoxicoformicina. Resultados en 6 pacientes. Sangre (Barc). 1990 Dec;35(6):421-4.
Montserrat E. Tratamiento de los linfomas no hodgkinianos. Med Clin (Barc). 1990 Dec 1;95(19):743-52.

1991

Montserrat E, Villamor N, Urbano-Ispizua A, Ribera JM, Rozman C. Alpha Interferon in chronic lymphocytic leukaemia. Eur J Cancer. 1991;27(Suppl 4):S74-7.
Rovira M, Feliu E, Florensa L, Woessner S, Tassies D, Montserrat E, Vives-Corrons JL, Rozman C. Acquired amegakaryocytic thrombocytopenic purpura associated with immunoglobulin deficiency. Acta Haematol. 1991;85(1):34-6.
Rozman M, Ribera JM, Ispizua AU, Matutes E, Villamor N, Vives Corrons JL, Montserrat E, Rozman C. Early Pre-B Lymphoblastic Transformation in A Patient with Refractory Anemia. Leuk Lymphoma. 1991;3(4):301-3.
Cervantes F, Salgado C, Feliu E, Montserrat E, Rozman C. Interferon alpha-2b for Essential Thrombocythaemia: Results in 13 Previously Untreated Patients. Leuk Lymphoma. 1991;4(5-6):351-4.
Rozman C, Montserrat E. Preface. Leuk Lymphoma. 1991;5(Suppl 1):i.
Montserrat E, Fontanilles M, Estapé J, Spanish Cooperative Group PETHEMA. Chronic lymphocytic leukemia treatment: an interim report of PETHEMA trials. Leuk Lymphoma. 1991;5(Suppl 1):89-92.
Pangalis GA, Reverter JC, Boussiotis VA, Montserrat E. Chronic Lymphocytic Leukemia in Younger Adults: Preliminary Results of a Study Based on 454 Patients-IWCLL/Working Group. Leuk Lymphoma. 1991; 5(Suppl 1):175-8.
Montserrat E, Viñolas N, Reverter JC, Rovira M, Rozman C. “Smouldering” Chronic Lymphocytic Leukemia. Leuk Lymphoma. 1991;5(Suppl 1):183-7.
Villamor N, Reverter JC, Martí JM, Montserrat E, Rozman C. Clinical features and response to treatment of infradiaphragmatic Hodgkin’s disease. Eur J Haematol. 1991 Jan;46(1):38-41.
Vallespí T, Montserrat E, Sanz MA. Chronic lymphocytic leukaemia: prognostic value of lymphocyte morphological subtypes. A multivariate survival analysis in 146 patients. Br J Haematol. 1991 Apr;77(4):478-85.
Cervantes F, Urbano-Ispizua A, Escoda L, Ordi J, Montserrat E, Rozman C. Crisis blástica linfoide T de la leucemia mieloide crónica cromosoma Filadelfia positiva: análisis de tres casos. Med Clin (Barc). 1991 Jun 1;97(1):21-3.
González-Clemente JM, Ribera JM, Campo E, Bosch X, Montserrat E, Grau JM. Ki-1+ anaplastic large-cell lymphoma of T-cell origin in an HIV-infected patient. AIDS. 1991 Jun;5(6):751-5.
Montserrat E, Villamor N, Urbano-Ispizua A, Ribera JM, Lozano M, Vives-Corrons JL, Rozman C. Treatment of early stage-B chronic lymphocytic leukemia with alpha-2b interferon after chlorambucil reduction of the tumoral mass. Ann Hematol. 1991 Jul;63(1):15-9.
Campo E, Cardesa A, Alos L, Palacin A, Cobarro J, Traserra J, Montserrat E. Non-Hodgkin’s lymphomas of nasal cavity and paranasal sinuses. An immunohistochemical study. Am J Clin Pathol. 1991 Aug;96(2):184-90.
Montserrat E, Gomis F, Vallespí T, Ríos A, Romero A, Soler J, Alcalá A, Morey M, Ferrán C, Díaz-Mediavilla J, Flores A, Woessner S, Batlle J, González-Aza C, Rovira M, Reverter JC, Rozman C. Presenting features and prognosis of chronic lymphocytic leukemia in younger adults. Blood. 1991 Sep 15;78(6):1545-51.
Tassies D, Montserrat E, Villamor N, Rozman C. CD11c positive B-chronic lymphocytic leukemia. Blood. 1991 Oct 1;78(7):1893.
Bladé J, López-Guillermo A, Tassies D, Montserrat E, Rozman C. Development of aggressive plasma cell leukaemia under interferon-alpha therapy. Br J Haematol. 1991 Nov;79(3):523-5.

1992

Baro J, Richard C, Sierra J, García-Conde J, García-Laraña J, Rocha E, Carrera D, León A, Zuazu J, Martínez F, Domingo A, Hernández F, Marín P, Iriondo A, Montserrat E, Conde E. Autologous bone marrow transplantation in 22 adult patients with lymphoblastic lymphoma responsive to conventional-dose chemotherapy. Bone Marrow Transplant. 1992;10:33-38.
Sanz C, Sierra J, Cobarro J, Avellaneda R, Montserrat E, Rozman C. An unusual case of Castleman’s disease restricted to the neck. ORL J Otorhinolaryngol Relat Spec. 1992;54(6):331-3.
Tassies D, Sierra J, Montserrat E, Martí R, Estrach T, Rozman C. Specific cutaneous involvement in Hodgkin’s disease. Hematol Oncol. 1992 Mar-Apr;10(2):75-9.
Blade J, Lopez-Guillermo A, Rozman C, Grañena A, Bruguera M, Bordas J, Cervantes F, Carreras E, Sierra J, Montserrat E. Chronic systemic candidiasis in acute leukemia. Ann Hematol. 1992 May;64(5):240-4.
Sacanella E, Cervantes F, Navarro M, Terol MJ, Estruch R, Montserrat E, Rozman C. Leucemia mieloide crónica después del tratamiento quimioterápico por linfoma no hodgkiniano. Med Clin (Barc). 1992 Jun 20;99(4):145-6.
Urbano-Ispizua A, Matutes E, Villamor N, Sierra J, Pujades A, Reverter JC, Feliu E, Cervantes F, Vives-Corrons JL, Montserrat E, Rozman C. The value of detecting surface and cytoplasmic antigens in acute myeloid leukaemia. Br J Haematol. 1992 Jun;81(2):178-83.
Villamor N, Reverter JC, Montserrat E, Urbano-Ispízua A, Vives-Corrons JL, Rozman C. Recombinant alpha-2b-interferon may restore natural-killer activity in patients with B-chronic lymphocytic leukemia. Leukemia. 1992 Jun;6(6):547-52.
Montserrat E, Binet JL, Catovsky D, Dighiero G, Gale RP, Rai KR, Rozman C. 5th International Workshop on Chronic Lymphocytic Leukemia. Leuk Res. 1992 Jun-Jul;16(6-7):717-20.
Blade J, Lopez-Guillermo A, Rozman C, Cervantes F, Salgado C, Aguilar JL, Vives-Corrons JL, Montserrat E. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br J Haematol. 1992 Jul;81(3):391-4.
Montserrat E, Gale RP, Rozman C. Bone marrow transplants for chronic lymphocytic leukaemia. Leukemia. 1992 Jul;6(7):619-22.
Bosch F, Cervantes F, Rozman M, Terol MJ, Montserrat E, Rozman C. Actividad de fosfatasa alcalina granulocitaria en la fase crónica y crisis blástica de la leucemia mieloide crónica. Estudio secuencial en 43 pacientes. Sangre (Barc). 1992 Aug;37(4):245-7.
Cervantes F, Urbano-Ispizua A, Pujades A, Bosch F, Vives-Corrons JL, Montserrat E, Rozman C. Análisis molecular en la leucemia mieloide crónica cromosoma Filadelfia negativa: estudio de seis casos. Med Clin (Barc). 1992 Sep 19;99(8):286-8.
Montserrat E. State of the Art Symposia: Prognostic factors and treatment of chronic lymphocytic leukemia. Br J Haematol. 1992 Sep;82:229-230.
López Guillermo A, Montserrat E. Linfomas de células grandes: El índice pronóstico internacional. Sangre (Barc). 1992 Oct;37(5):329-30.
Rozman C, Montserrat E. Newer aspects of prognosis in chronic lymphocytic leukemia. Leukemia. 1992 Nov;6(Suppl 4):137-9.
Bosch F, Cervantes F, Lopez-Guillermo A, Carreras E, Montserrat E, Rozman C. Polycythaemia vera following non-Hodgkin’s lymphoma. Leuk Lymphoma. 1992 Dec;8(6):501-2.
Escorsell A, López-Guillermo A, Blade J, Villamor N, Massanes F, Montserrat E, Rozman C. Infiltración meníngea en el mieloma múltiple. Estudio de un nuevo caso y revisión de la bibliografía. Rev Clin Esp. 1992 Dec;191(9):478-80.

1993

Montserrat E. Chronic lymphocytic leukemia in early stage: “smoldering” and “active” forms. In: Cheson B, ed. Chronic Lymphocytic Leukemia: Scientific Advances and Clinical Developments. New York, NY: Marcel Dekker; 1993:281-296.
Salgado C, Feliu E, Montserrat E, Villamor N, Ordi J, Aguilar JL, Vives-Corrons JL, Rozman C. B-type large-cell primary splenic lymphoma with massive involvement of the red pulp. Acta Haematol. 1993;89(1):46-9.
Cervantes F, Urbano-Ispizua A, Villamor N, Feliu E, Milla F, Lopez-Guillermo A, Ribera JM, Granada I, Vives-Corrons JL, Montserrat E, Rozman C. Ph-positive chronic myeloid leukemia mimicking essential thrombocythemia and terminating into megakaryoblastic blast crisis: report of two cases with molecular studies. Leukemia. 1993 Feb;7(2):327-30.
Sierra J, Conde E, Montserrat E. Autologous bone marrow transplantation for non-Hodgkin’s lymphoma in first remission. Blood. 1993 Apr 1;81(7):1968-9.
Bosch F, Ordi J, López-Guillermo A, Campo E, Montserrat E, Rozman C. Enfermedad de Hodgkin y linfoma no hodgkiniano de presentación simultánea. Med Clin (Barc). 1993 May 22;100(20):788-90.
Lopez-Guillermo A, Montserrat E, Reverter JC, Cervantes F, Escoda L, Tassies D, Blade J, Marin P, Sierra J, Ordi J, Rozman C. Large-cell lymphoma: a study of prognostic factors and assessment of five recently proposed predictive systems. Leuk Lymphoma. 1993 May;10(1-2):101-9.
Montserrat E, López-Guillermo A, Rozman C. B-cell low-grade malignant lymphomas. In: Lechner K, Gadner H, eds. Haematology Trends ’93. Proceedings of the Educational Programme of the XIIth Meeting of the International Society of Haematology (European and African Division). Vienna, August 28 – September 3, 1993. Stuttgart, Germany; New York, NY: Schattauer; 1993: 56-79.
Montserrat E, Rozman C. Chronic lymphocytic leukaemia treatment. Blood Rev. 1993 Sep;7(3):164-75.
Urbano-Ispizua A, Cervantes F, Matutes E, Villamor N, Pujades A, Sierra J, Feliu E, Vives-Corrons JL, Montserrat E, Rozman C. Immunophenotypic characteristics of blast crisis of chronic myeloid leukaemia: correlations with clinico-biological features and survival. Leukemia. 1993 Sep;7(9):1349-54.
Sierra J, Conde E, Iriondo A, Brunet S, Marín J, Pérez de Oteiza J, Caballero D, Martínez F, León A, García-Conde J, Hernández-Navarro F, Domingo A, Carrera D, Reverter JC, Richard C, Zuazu J, Baro J, Rifón J, Solano C, Díaz-Mediavilla J, Rozman C, Montserrat E. Frozen vs. non-frozen bone marrow for autologous transplantation in lymphomas: a report from the Spanish GEL/TAMO Cooperative Group. Ann Hematol. 1993; 67(3): 111-114.
Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G, Cabanillas F, Canellos GP, Coiffier B, Connors JM, Cowan RA, Crowther D, Dahlberg S, Engelhard M, Fusher RI, Gisselbrecht Ch, Horning SJ, Lepage E, Lister A, Meerwaldt JH, Montserrat E, Nissen NI, Oken MM, Peterson BA, Tondini C, Velasquez WS, Yeap BY. A predictive model for aggressive non-Hodgkin’s lymphoma: the international non-Hodgkin’s lymphoma prognostic factors project. N Engl J Med. 1993 Sep 30; 329(14): 987-994.
Cervantes F, Alcorta I, Escoda L, Montserrat E, Rozman C. Tratamiento con interferón alfa de la mielofibrosis idiopática. Med Clin (Barc). 1993 Oct 23;101(13):498-500.
Merino A, Urbano-Ispizua A, Marín P, Besson I, Carreras E, Sierra J, Salgado C, Rovira M, Grañena A, Montserrat E, Vives-Corrons JLL, Rozman C. Estudio inmunofenotípico de las fracciones medulares obtenidas mediante elutriación en el trasplante alogénico de medulla ósea. Sangre (Barc). 1993 Oct;38(5):359-64.
Salgado C, Bladé J, López-Guillermo A, Cervantes F, Montserrat E, Rozman C. Mieloma múltiple tras gammapatía monoclonal de significado incierto: Estudio de 10 pacientes. Sangre (Barc). 1993 Oct;38(5):371-4.
Montserrat E, Rozman C. Chronic lymphocytic leukaemia: prognostic factors and natural history. Baillieres Clin Haematol. 1993 Dec;6(4):849-66.
Gale RP, Montserrat E. Intensive therapy of chronic lymphocytic leukaemia. Baillieres Clin Haematol. 1993 Dec;6(4):879-85.

1994

Conde E, Sierra J, Iriondo A, Domingo A, García Laraña J, Marín J, Caballero D, Martínez F, León A, García-Conde J, Hernández F, Carrera D, Mataix R, Zuazu J, Cuesta B, Díaz Mediavilla J, Lahuerta JJ, Richard C, Baro J, Montserrat E. Prognostic factors in patients who received autologous bone marrow transplantation for non-Hodgkin’s lymphoma. Report of 104 patients from the Spanish Cooperative Group GEL/TAMO. Bone Marrow Transplant. 1994;14:279-286.
Montserrat E, Rozman C. Current approaches to the treatment and management of chronic lymphocytic leukaemia. Drugs. 1994;47(Suppl 6):1-9.
Montserrat E, Binet JL, Dighiero G, Gale RP, Juliusson G, Keating M, Rai KR. Chronic lymphoproliferative disorders. Rev Invest Clin. 1994 Apr;Suppl:52-8.
López-Guillermo A, Montserrat E, Bosch F, Terol MJ, Campo E, Rozman C. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol. 1994 Jul;12(7):1343-8.
Zucca E, Stein H, Coiffier B, European Lymphoma Task Force. European Lymphoma Task Force (ELTF): Report of the workshop on mantle-cell lymphoma (MCL). Ann Oncol. 1994 Jul; 5(6): 507-511.
Bataller R, Urbano-Ispizua A, Luburich P, Montserrat E, Rozman C. Cavitación pulmonar como manifestación inicial de una enfermedad de Hodgkin. Med Clin (Barc). 1994 Sep 24;103(9):342-3.
Bladé J, López-Guillermo A, Bosch F, Cervantes F, Reverter JC, Montserrat E, Rozman C. Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. Br J Haematol. 1994 Sep;88(1):117-21.
Gale RP, Caligaris-Cappio F, Dighiero G, Keating M, Montserrat E, Rai K. Recent progress in chronic lymphocytic leukemia. International Workshop on chronic Lymphocytic Leukemia. Leukemia. 1994 Sep;8(9):1610-4.
Lopez-Guillermo A, Montserrat E, Bosch F, Escoda L, Terol MJ, Marin P, Reverter JC, Blade J, Cervantes F, Sierra J, Nomdedeu B, Urbano-Ispizua A, Rouira M, Carreras E, Campo E, Rozman C. Low-grade lymphoma: clinical and prognostic studies in a series of 143 patients from a single institution. Leuk Lymphoma. 1994 Sep;15(1-2):159-65.
Bosch F, Jares P, Campo E, Lopez-Guillermo A, Piris MA, Villamor N, Tassies D, Jaffe ES, Montserrat E, Rozman C, Cardesa A. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood. 1994 Oct 15;84(8):2726-32.
Solé F, Bosch F, Woessner S, Pérez-Losada A, Cervantes F, Montserrat E, Florensa L, Rozman C. Refractory anemia with excess of blasts and isochromosome 12p in a patient with primary mediastinal germ-cell tumor. Cancer Genet Cytogenet. 1994 Oct 15;77(2):111-3.
Terol MJ, Tassies D, López-Guillermo A, Martín-Ortega E, Bladé J, Cervantes F, García C, Montserrat E, Rozman C. Sepsis por Candida tropicalis en pacientes granulocitopénicos. Estudio de 10 casos. Med Clin (Barc). 1994 Nov 5;103(15):579-82.

1995

Montserrat E. The never ending story. Med Clin (Barc). 1995 Jan 21;104(2):79.
Sierra J, Carreras E, Rovira M, Batlle M, Urbano-Ispizua A, Marín P, Besson I, Merino A, Algara M, Cervantes F, Valls A, Castillo R, Montserrat E, Rozman C. Trasplante de médula ósea a partir de donantes no emparentados en la leucemia mieloide crónica: resultados en 15 pacientes. Med Clin (Barc). 1995;104:689-694.
Salgado C, Urbano-Ispizua A, Rozman C, Sierra J, Carreras E, Montserrat E. Interleukin-2 after T-cell-depleted allogeneic bone marrow transplantation. Blood. 1995 Jan 15;85(2):600-1.
Martínez-Francés A, Lopez-Guillermo A, Esteve J, Bosch F, Terol MJ, Montserrat E, Rozman C. Características de los pacientes con linfoma de bajo grado de malignidad y larga supervivencia. Sangre (Barc). 1995 Feb;40(1):53-7.
Montserrat E, Campo E. Una nueva clasificación internacional de las neoplasias linfoides. ¿Adiós a la Working Formulation, Kiel y compañía? Med Clin (Barc). 1995 Feb 11;104(5):185-7.
Bladé J, Carreras E, Rozman C, Sierra J, Rovira M, Batlle M, Valls A, Algara M, Marín P, Urbano-Ispizua A, Merino A, Montserrat E. Trasplante alogénico de medula ósea en el mieloma múltiple. Análisis de 12 casos consecutives. Med Clin (Barc). 1995;105:1-4.
Montserrat E, Rozman C. Chronic lymphocytic leukemia: present status. Ann Oncol. 1995 Mar;6(3):219-35.
Rovira A, Urbano-Ispizua A, Cervantes F, Rozman M, Vives-Corrons JL, Montserrat E, Rozman C. P53 tumor suppressor gene in chronic myelogenous leukemia: a sequential study. Ann Hematol. 1995 Mar;70(3):129-33.
Esteve J, López-Guillermo A, Martínez-Francés A, Bosch F, Terol MJ, Campo E, Montserrat E, Rozman C. Presenting features, natural history, and prognostic factors in localized non-Hodgkin’s lymphomas: analysis of 117 cases from a single institution. Eur J Haematol. 1995 Oct;55(4):217-22.
Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995 Oct 19;333(16):1052-7.
Tàssies D, Montserrat E, Reverter JC, Villamor N, Rovira M, Rozman C. Myelomonocytic antigens in B-cell chronic lymphocytic leukemia. Leuk Res. 1995 Nov;19(11):841-8.
Cobo F, Cervantes F, Martinez C, Salgado C, Blade J, Montserrat E, Rozman C. Multiple myeloma following essential thrombocythemia. Leuk Lymphoma. 1995 Dec;20(1-2):177-9.
Torra R, Bladé J, Cases A, López-Pedret J, Montserrat E, Rozman C, Revert L. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol. 1995 Dec;91(4):854-9.
Bosch F, Campo E, Jares P, Pittaluga S, Muñoz J, Nayach I, Piris MA, Dewolf-Peeters C, Jaffe ES, Rozman C, Montserrat E, Cardesa A. Increased expression of the PRAD1/CCND1 gene in hairy-cell leukaemia. Br J Haematol. 1995 Dec;91(4):1025-1030.

1996

Escoda L, Urbano-Ispizua A, Montserrat E, Ordi J, López-Guillermo A, Matutes E, Reeves J, Schulz TF, Rozman C. Adult T-Cell Leukaemia-Lymphoma Relapsing as Hodgkin Disease Nodular Sclerosis Subtype. Hematology. 1996;1(1):85-8.
Rozman C, Urbano-Ispizua A, Carreras E, Sierra J, Marín P, Rovira M, Merino A, Batlle M, Briones J, Mazzara R, Montserrat E. Trasplante alogénico de progenitores hemopoyéticos de sangre periférica. Experiencia preliminar. Med Clin (Barc). 1996 Jan 20;106(2):66-8.
Michallet M, Archimbaud E, Bandini G, Rowlings PA, Deeg HJ, Gahrton G, Montserrat E, Rozman C, Gratwohl A, Gale RP. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann Intern Med. 1996 Feb 1;124(3):311-5.
Rozman C, Urbano-Ispizua A, Carreras E, Sierra J, Marin P, Rovira M, Merino A, Batlle M, Briones J, Mazzara R, Montserrat E. Allogenic transplants with peripheral blood progenitor cells: a report of six cases. Leuk Lymphoma. 1996 Feb;20(5-6):471-4.
Rozman C, Montserrat E. Chronic Lymphocytic Leukemia. New Engl J Med. 1996 Feb 15; 334(7): 472-473.
Esteve J, Cervantes F, Bosch F, Cobo F, Montserrat E, Rozman C. Tratamiento con interferon alfa del síndrome hipereosinofílico idiopático resistente a la terapéutica convencional. Med Clin (Barc). 1996 Mar 2;106(8):304-6.
Montserrat E, Bosch F, López-Guillermo A, Graus F, Terol MJ, Campo E, Rozman C. CNS involvement in mantle-cell lymphoma. J Clin Oncol. 1996 Mar;14(3):941-4.
Rozman C, Montserrat E. Clinical research at the postgraduate school of haematology ‘Farreras-Valentí’. Clin Sci (Lond). 1996 Mar;90(3):167-9.
Briones J, Urbano-Ispizua A, Rozman C, Marín P, Carreras E, Rovira M, Sierra J, Colomer D, Martínez C, Montserrat E. Study of hematopoietic chimerism following allogeneic peripheral blood stem cell transplantation using PCR amplification of short tandem repeats. Ann Hematol. 1996 Apr;72(4):265-8.
Hernandez L, Fest T, Cazorla M, Teruya-Feldstein J, Bosch F, Peinado MA, Piris MA, Montserrat E, Cardesa A, Jaffe ES, Campo E, Raffeld M. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood. 1996 Apr 15;87(8):3351-9.
Martínez C, Urbano-Ispizua A, Rozman C, Marín P, Mazzara R, Carreras E, Rovira M, Sierra J, Briones J, Ordinas A, Montserrat E. Effects of G-CSF administration and peripheral blood progenitor cell collection in 20 healthy donors. Ann Hematol. 1996 Apr;72(4):269-72.
Montserrat E, Villamor N, Reverter JC, Brugués RM, Tàssies D, Bosch F, Aguilar JL, Vives-Corrons JL, Rozman M, Rozma C. Bone marrow assessment in B-cell chronic lymphocytic leukaemia: aspirate or biopsy? A comparative study in 258 patients. Br J Haematol. 1996 Apr;93(1):111-6.
Sierra J, Brunet S, Grañena A, Olivé T, Bueno J, Ribera JM, Petit J, Besses C, Llorente A, Guardia R, Macía J, Rovira M, Badell I, Vela E, Díaz de Heredia C, Vivancos P, Carreras E, Feliu E, Montserrat E, Julía A, Cubells J, Rozman C, Domingo A, Ortega JJ. Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Catalan Group for Bone Marrow Transplantation. J Clin Oncol. 1996 Apr;14(4):1353-63.
Briones J, Cervantes F, Montserrat E, Rozman C. Hypercalcemia in a patient with chronic lymphocytic leukemia evolving into Richter’s syndrome. Leuk Lymphoma. 1996 May;21(5-6):521-3.
Jares P, Campo E, Pinyol M, Bosch F, Miquel R, Fernandez PL, Sanchez-Beato M, Soler F, Perez-Losada A, Nayach I, Mallofré C, Piris MA, Montserrat E, Cardesa A. Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity. Am J Pathol. 1996 May;148(5):1591-600.
Montserrat E, Lopez-Lorenzo JL, Manso F, Martin A, Prieto E, Arias-Sampedro J, Fernandez MN, Oyarzabal FJ, Odriozola J, Alcala A, Garcia-Conde J, Guardia R, Bosch F. Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience. Leuk Lymphoma. 1996 May;21(5-6):467-72. https://doi.org/10.3109/10428199609093445
Pinyol M, Campo E, Nadal A, Terol MJ, Jares P, Nayach I, Fernandez PL, Piris MA, Montserrat E, Cardesa A. Detection of the bcl-1 rearrangement at the major translocation cluster in frozen and paraffin-embedded tissues of mantle cell lymphomas by polymerase chain reaction. Am J Clin Pathol. 1996 May;105(5):532-7. https://doi.org/10.1093/ajcp/105.5.532
Cobo F, Pereira A, Nomdedeu B, Gallart T, Ordi J, Torne A, Montserrat E, Rozman C. Ovarian dermoid cyst-associated autoimmune hemolytic anemia: A case report with emphasis on pathogenic mechanisms. Am J Clin Pathol. 1996 May;105(5):567-571.
Briones J, Montserrat E, Urbano-Ispizua A, Esteve J, Colomer D, López-Guillermo A, Bosch F, Hadjieu E, Rozman C. Tratamiento con fludarabina de neoplasias linfoides de bajo grado de malignidad resistentes al tratamiento o en recaída. Med Clin (Barc). 1996 Jun 15;107(3):86-9.
Cervantes F, Briones J, Bruguera M, Font C, Grau JM, Rozman C, Montserrat E. Hodgkin’s disease presenting as a cholestatic febrile illness: incidence and main characteristics in a series of 421 patients. Ann Hematol. 1996 Jun;72(6):357-60.
Martínez C, Urbano-Ispizua A, Mazzara R, Rozman C, Montserrat E. Granulocyte colony-stimulating factor administration and peripheral blood progenitor cells collection in normal donors: analysis of leukapheresis-related side effects. Blood. 1996 Jun 1;87(11):4916-7.
Sanz L, Cervantes F, Mercader JM, Rozman M, Rozman C, Montserrat E. Afección occulta de la médula ósea en la enfermedad de Hodgkin: detección por resonancia magnética. Med Clin (Barc). 1996 Jun 22;107(4):143-5.
Bladé J, San Miguel JF, Fontanillas M, Alcalá A, Maldonado J, García-Conde J, Conde E, Conzález-Brito G, Moro MJ, Escudero ML, Trujillo J, Pascual A, Rozman C, Estapé J, Montserrat E. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated. J Clin Oncol. 1996 Jul;14(7):2167-73.
Cervantes F, Colomer D, Vives-Corrons JL, Rozman C, Montserrat E. Chronic myeloid leukemia of thrombocythemic onset: a CML subtype with distinct hematological and molecular features? Leukemia. 1996 Jul;10(7):1241-3.
Bladé J, Muñoz M, Fontanillas M, San Miguel J, Alcalá A, Maldonado J, Besses C, Moro MJ, García-Conde J, Rozman C, Montserrat E, Estapé J. Treatment of multiple myeloma in elderly people: long-term results in 178 patients. Age Ageing. 1996 Sep;25(5):357-61.
Terol MJ, Cid MC, López-Guillermo A, Juan M, Yagüe J, Miralles A, Vilella R, Vives J, Cardesa A, Montserrat E, Campo E. Expression of intercellular adhesion molecule-3 (ICAM-3/CD50) in malignant lymphoproliferative disorders and solid tumors. Tissue Antigens. 1996 Oct;48(4 Pt 1):271-7.
Cervantes F, López-Guillermo A, Bosch F, Terol MJ, Rozman C, Montserrat E. An assessment of the clinicohematological criteria for the accelerated phase of chronic myeloid leukemia. Eur J Haematol. 1996 Oct;57(4):286-91.
Montserrat E, Hallek M. Current strategies for the treatment of CLL. Leuk Lymphoma. 1996 Oct;22(Suppl 2):65-8.
Sanz L, Cervantes F, Esteve J, Vilardell J, Marín P, Rozman C, Montserrat E. Leucemia mieloide crónica tras trasplante renal: Aportación de un nuevo caso y revision de la bibliografía. Sangre (Barc). 1996 Oct;41(5):391-3.
Montserrat E, García-Conde J, Viñolas N, López-Guillermo A, Hernández-Nieto L, Zubizarreta A, Maldonado J, Alcalá A, Faura MV, Llorente A, Bladé J, Fontanillas M, Estapé J. CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin’s lymphomas: long-term results of a multicenter randomized trial. (PETHEMA: Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hematology). Eur J Haematol. 1996 Nov;57(5):377-83.
Cobo F, Cervantes F, García-Pagán JC, Bosch J, Rozman C, Montserrat E. Síndrome de Budd-Chiari asociado a síndromes mieloproliferativos crónicos: análisis de seis casos. Med Clin (Barc). 1996 Nov 16;107(17):660-3.

1997

Rozman C, Montserrat E. Chronic Lymphocytic Leukemia: An Update on Current Treatment Approaches. Hematology. 1997;2(1):1-9.
Montserrat E, Bosch F, Rozman C. B-cell chronic lymphocytic leukemia: recent progress in biology, diagnosis, and therapy. Ann Oncol. 1997;8(Suppl 1):93-101.
Montserrat E. Chronic lymphoproliferative disorders. Curr Opin Oncol. 1997 Jan;9(1):34-41.
Pinyol M, Hernandez L, Cazorla M, Balbín M, Jares P, Fernandez PL, Montserrat E, Cardesa A, Lopez-Otín C, Campo E. Deletions and loss of expression of p16^INK4a and p21^Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood. 1997 Jan 1;89(1):272-80.
Carreras E, Sierra J, Rovira M, Urbano-Ispizua A, Martinez C, Nomdedeu B, Cervantes F, Marín P, Rozman C, Montserrat E. Successful autografting in chronic myelogenous leukaemia using Philadelphia negative blood progenitor cells mobilized with rHuG-CSF alone in a patient responding to alpha-interferon. Br J Haematol. 1997 Feb;96(2):421-3.
Rozman M, Mercader JM, Aguilar JL, Montserrat E, Rozman C. Estimation of bone marrow cellularity by means of vertebral magnetic resonance. Haematologica. 1997 Mar-Apr;82(2):166-70.
Manasanch L, Carreras E, Montserrat E. Coste económico del trasplante autólogo de progenitores hematopoyéticos. Med Clin (Barc). 1997 Apr 12;108(14):558.
Setoain FJ, Pons F, Herranz R, Vidal-Sicart S, Lomeña F, Ayuso C, Montserrat E, Setoain J. 67Ga scintigraphy for the evaluation of recurrences and residual masses in patients with lymphoma. Nucl Med Commun. 1997 May;18(5):405-11.
Rozman C, Carreras E, Sierra J, Rovira M, Urbano-Ispizua A, Marín P, Bladé J, Cervantes F, López-Guillermo A, Nomdedeu B, Rozman M, Aguilar JL, Vives-Corrons JL, Mazzara R, Ordinas A, Ribera JM, Feliu E, Castillo R, Grañena A, Montserrat E. Trasplante de progenitores hemopoyéticos: 20 años de experiencia en la Escuela de Hematología «Farreras-Valentí»/Hospital Clínic de Barcelona. Med Clin (Barc). 1997 May 10;108(18):681-6.
Cervantes F, Pereira A, Esteve J, Rafel M, Cobo F, Rozman C, Montserrat E. Identification of ‘short-lived’ and ‘long-lived’ patients at presentation of idiopathic myelofibrosis. Br J Haematol. 1997 Jun;97(3):635-40.
Rozman C, Bosch F, Montserrat E. Chronic lymphocytic leukemia: a changing natural history? Leukemia. 1997 Jun;11(6):775-8.
Urbano-Ispizua A, Rozman C, Martínez C, Marín P, Briones J, Rovira M, Féliz P, Viguria MC, Merino A, Sierra J, Mazzara R, Carreras E, Montserrat E. Rapid engraftment without significant graft-versus-host disease after allogeneic transplantation of CD34+ selected cells from peripheral blood. Blood. 1997 Jun 1;89(11):3967-73.
Montserrat E, Bosch F, Rozman C. Treatment of B-cell chronic lymphocytic leukaemia: current status and future perspectives. J Intern Med Suppl. 1997 Jul;740:63-7.
Rozman C, Brugués R, Montserrat E. About the prognostic value of bone marrow histopathological patterns in B-cell chronic lymphocytic leukaemia. Eur J Haematol. 1997 Jul;59(1):61-2.
Esteve J, Cervantes F, Rives S, Rozman M, Zarco MA, Montserrat E. Simultaneous occurrence of B-cell chronic lymphocytic leukemia and chronic myeloid leukemia with further evolution to lymphoid blast crisis. Haematologica. 1997 Sep-Oct;82(5):596-9.
Martínez C, Carreras E, Sierra J, Rovira M, Urbano-Ispizua A, Viguria MC, Vela D, Rozman C, Montserrat E. Segudo trasplante alogénico de progenitores hematopoyéticos como tratamiento de la recaída leucémica: resultados en 10 pacientes. Med Clin (Barc). 1997 Oct 4;109(11):401-5.
Montserrat E. New therapeutic issues in CLL. Hematol Cell Ther. 1997 Nov;39(Suppl 1):S45-9.
Cervantes F, Pereira A, Esteve J, Cobo F, Rozman C, Montserrat E. Mielofibrosis idiopática: características iniciales, patrones evolutivos y supervivencia en una serie de 106 pacientes. Med Clin (Barc). 1997 Nov 15;109(17):651-5.
Cobo F, Montserrat E, Campo E. Linfoma primario de cavidades: una nueva entidad clinicopatológica. Med Clin (Barc). 1997 Nov 22;109(18):712-4.

1998

Montoto S, Bosch F, Estrach T, Bladé J, Nomdedeu B, Montserrat E. Pyoderma gangrenosum triggered by α2b-interferon in a patient with chronic granulocytic leukemia. Leuk Lymphoma. 1998;30(1-2):199-202.
Terol MJ, López-Guillermo A, Bosch F, Villamor N, Cid MC, Rozman C, Campo E, Montserrat E. Expression of the adhesion molecule ICAM-1 in non-Hodgkin’s lymphoma: relationship with tumor dissemination and prognostic importance. J Clin Oncol. 1998 Jan;16(1):35-40.
Cervantes F, Villamor N, Esteve J, Montoto S, Rives S, Rozman C, Montserrat E. ‘Lymphoid’ blast crisis of chronic myeloid leukaemia is associated with distinct clinicohaematological features. Br J Haematol. 1998 Jan;100(1):123-8.
Briones J, Urbano-Ispizua A, Orfao A, Marín P, Sierra J, Rovira M, Carreras E, Rozman C, Montserrat E. Demonstration of donor origin of CD34+ HLA-DR- bone marrow cells after allogeneic peripheral blood transplantation with a long follow-up. Bone Marrow Transplant. 1998 Jan;21(2):189-94.
Hernández-Boluda JC, Sierra J, Esteve J, Nomdedeu B, Montserrat E. Treatment of elderly patients with AML: results of an individualized approach. Haematologica. 1998 Jan;83(1):34-9.
Bosch F, López-Guillermo A, Campo E, Ribera JM, Conde E, Piris MA, Vallespí T, Woessner S, Montserrat E. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer. 1998 Feb 1;82(3):567-75.
Cervantes F, Pereira A, Esteve J, Cobo F, Rozman C, Montserrat E. The changing profile of idiopathic myelofibrosis: a comparison of the presenting features of patients diagnosed in two different decades. Eur J Haematol. 1998 Feb;60(2):101-5.
Esteve J, Villamor N, Colomer D, Bosch F, López-Guillermo A, Rovira M, Urbano-Ispizua A, Sierra J, Carreras E, Montserrat E. Hematopoietic stem cell transplantation in chronic lymphocytic leukemia: a report of 12 patients from a single institution. Ann Oncol. 1998 Feb;9(2):167-72.
Sanz L, Bladé J, Olondo M, Rozman M, Mercader JM, Rozman C, Montserrat E. Contribución de la resonancia magnética en el diagnóstico diferencial de un colapso vertebral en un paciente con myeloma múltiple. Sangre (Barc). 1998 Feb;43(1):77-81.
Hernández S, Hernández L, Beà S, Cazorla M, Fernández PL, Nadal A, Muntané J, Mallofré C, Montserrat E, Cardesa A, Campo E. cdc25 cell cycle-activating phosphatases and c-myc expression in human non-Hodgkin’s lymphomas. Cancer Res. 1998 Apr 15;58(8):1762-7.
Pinyol M, Cobo F, Bea S, Jares P, Nayach I, Fernandez PL, Montserrat E, Cardesa A, Campo E. p16^INK4a gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin’s lymphomas. Blood. 1998 Apr 15;91(8):2977-84.
Briones J, Urbano-Ispizua A, Lawler M, Rozman C, Gardiner N, Marín P, Salgado C, Féliz P, McCann S, Montserrat E. High frequency of donor chimerism after allogeneic transplantation of CD34+-selected peripheral blood cells. Exp Hematol. 1998 May;26(5):415-20.
Serra A, Estrach MT, Martí R, Villamor N, Rafel M, Montserrat E. Cutaneous involvement as the first manifestation in a case of T-cell prolymphocytic leukaemia. Acta Derm Venereol. 1998 May;78(3):198-200.
Sans M, Andreu V, Bordas JM, Llach J, López-Guillermo A, Cervantes F, Bruguera M, Mondelo F, Montserrat E, Terés J, Rodés J. Usefulness of laparoscopy with liver biopsy in the assessment of liver involvement at diagnosis of Hodgkin’s and non-Hodgkin’s lymphomas. Gastrointest Endosc. 1998 May;47(5):391-5.
López-Guillermo A, García-Conde J, Alvarez-Carmona AM, León P, Maldonado J, Alcalá A, Zubizarreta A, Sancho-Tello R, Carbonell F, Contreras E, Besses C, Hernando A, Fontanillas M, Montserrat E. Comparación de lal quimioterapia CHOP frente a CHOP/VIA para el tratamiento de los linfomas no hodgkinianos agresivos: estudio multicéntrico aleatorizado en 132 pacientes. Med Clin (Barc). 1998 May 9;110(16):601-4.
Rafel M, Cobo F, Cervantes F, Bosch F, Campo E, Montserrat E. Transient pancytopenia after non-A non-B non-C acute hepatitis preceding acute lymphoblastic leukemia. Haematologica. 1998 Jun;83(6):564-6.
Rafel M, Esteve J, Cervantes F, Velasco M, Serra A, Campo E, Montserrat E. Linfoma primario de mama tipo MALT. Sangre (Barc). 1998 Jun;43(3):244-7.
Bladé J, San Miguel JF, Escudero ML, Fontanillas M, Besalduch J, Gardella S, Arias J, García-Conde J, Carnero M, Marti JM, Rozman C, Estapé J, Montserrat E. Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology). Leukemia. 1998 Jul;12(7):1144-8.
Villamor N, Zarco MA, Rozman M, Ribera JM, Feliu E, Montserrat E. Acute myeloblastic leukemia with minimal myeloid differentiation: phenotypical and ultrastructural characteristics. Leukemia. 1998 Jul;12(7):1071-5.
Sanz L, López-Guillermo A, Martínez C, Bosch F, Esteve J, Cobo F, Montoto S, Perales M, Bladé J, Cervantes F, Nomdedeu B, Campo E, Montserrat E. Risk of relapse and clinico-pathological features in 103 patients with diffuse large-cell lymphoma in complete response after first-line treatment. Eur J Haematol. 1998 Jul;61(1):59-64.
Cervantes F, Barosi G, Demory JL, Reilly J, Guarnone R, Dupriez B, Pereira A, Montserrat E. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol. 1998 Aug;102(3):684-90.
Bellosillo B, Piqué M, Barragán M, Castaño E, Villamor N, Colomer D, Montserrat E, Pons G, Gil J. Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells. Blood. 1998 Aug 15;92(4):1406-14.
Campo E, Gaulard P, Zucca E, Jaffe ES, Harris NL, Diebold J, Schlegelberger B, Feller AC, Delsol G, Gisselbrecht C, Montserrat E. Report of the European Task Force on Lymphomas: workshop on peripheral T-cell lymphomas. Ann Oncol. 1998 Aug;9(8):835-43.
López-Guillermo A, Cid J, Salar A, López A, Montalbán C, Castrillo JM, González M, Ribera JM, Brunet S, García-Conde J, Fernández de Sevilla A, Bosch F, Montserrat E. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol. 1998 Aug;9(8):849-55.
Bladé J, Fernández-Llama P, Bosch F, Montolíu J, Lens XM, Montoto S, Cases A, Darnell A, Rozman C, Montserrat E. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998 Sep 28;158(17):1889-93.
Perales M, Cervantes F, Cobo F, Montserrat E. Non-Hodgkin’s lymphoma associated with Gaucher’s disease. Leuk Lymphoma. 1998 Nov;31(5-6):609-12.
Montserrat E, Rozman C. Haematology. Important steps forward. Lancet. 1998 Dec 19-26;352(Suppl 4):SIV13.
Filella X, Bladé J, Montoto S, Molina R, Coca F, Montserrat E, Ballesta AM. Impaired production of interleukin 6 and tumour necrosis factor alpha in whole blood cell cultures of patients with multiple myeloma. Cytokine. 1998 Dec;10(12):993-6.

1999

Montserrat E. Chronic lymphocytic leukemias. In Degos L, Linch DC, Löwenberg B, eds. Textbook of Malignant Haematology. London, UK: Martin Dunitz Ltd; 1999: 563-591.
Martínez C, Urbano-Ispizua A, Rozman M, Rovira M, Marín P, Montfort N, Carreras E, Montserrat E. Effects of short-term administration of G-CSF (filgrastim) on bone marrow progenitor cells: analysis of serial marrow samples from normal donors. Bone Marrow Transplant. 1999 Jan;23(1):15-9.
Camós M, Cervantes F, Montoto S, Hernández-Boluda JC, Villamor N, Montserrat E. Acute lymphoid leukemia following polycythemia vera. Leuk Lymphoma. 1999 Jan;32(3-4):395-8. https://doi.org/10.3109/10428199909167404
Hernández-Boluda JC, Marín P, Carreras E, Aguilar JL, Grañena A, Rozman C, Montserrat E. Bone marrow transplantation for severe aplastic anemia: the Barcelona Hospital Clinic experience. Haematologica. 1999 Jan;84(1):26-31.
Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Coiffier B, Philip T. International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin’s lymphomas: report of the jury. Ann Oncol. 1999 Jan;10(1):13-9.
Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Philip T, Coiffier B. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin’s Lymphomas: report of the jury. J Clin Oncol. 1999 Jan;17(1):423-9.
Besses C, Cervantes F, Pereira A, Florensa L, Solé F, Hernández-Boluda JC, Woessner S, Sans-Sabrafen J, Rozman C, Montserrat E. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia. 1999 Feb;13(2):150-4.
Martínez C, Urbano-Ispizua A, Rozman C, Marín P, Rovira M, Sierra J, Montfort N, Carreras E, Montserrat E. Immune reconstitution following allogeneic peripheral blood progenitor cell transplantation: comparison of recipients of positive CD34+ selected grafts with recipients of unmanipulated grafts. Exp Hematol. 1999 Mar;27(3):561-8.
Rozman C, Cervantes F, Rozman M, Mercader JM, Montserrat E. Magnetic resonance imaging in myelofibrosis and essential thrombocythaemia: contribution to differential diagnosis. Br J Haematol. 1999 Mar;104(3):574-80.
Cervantes F, Hernández-Boluda JC, Ferrer A, Cid J, Montserrat E. The changing profile of Ph-positive chronic myeloid leukemia at presentation: possible impact of earlier diagnosis on survival. Haematologica. 1999 Apr;84(4):324-7.
Espinet B, Solé F, Woessner S, Bosch F, Florensa L, Campo E, Costa D, Lloveras E, Vilà RM, Besses C, Montserrat E, Sans-Sabrafen J. Translocation (11;14)(q13;q32) and preferential involvement of chromosomes 1, 2, 9, 13, and 17 in mantle cell lymphoma. Cancer Genet Cytogenet. 1999 May;111(1):92-8.
Rives S, Camós M, Bosch F, Esteve J, Villamor N, Montserrat E. Central nervous system involvement in acute promyelocytic leukemia. A description of two cases and review of the literature. Haematologica. 1999 May;84(5):473-4.
Wendtner CM, Schmitt B, Wilhelm M, Dreger P, Montserrat E, Emmerich B, Hallek M. Redefining the therapeutic goals in chronic lymphocytic leukemia: towards an evidence-based, risk-adapted therapy. Ann Oncol. 1999 May;10(5):505-9.
Hernández-Boluda JC, Cervantes F, Camós M, Costa D, Rafel M, Montserrat E. Leucemia mieloide crónica cromosoma Filadelfia positivo en sujetos de edad avanzada: características iniciales, historia natural y supervivencia. Med Clin (Barc). 1999 May 1;112(15):565-7.
Ferrer A, López-Guillermo A, Bosch F, Montoto S, Hernández-Boluda JC, Camós M, Miquel R, Campo E, Montserrat E. Linfomas del tejido linfoide asociado a mucosas (MALT) de localización extragástrica: análisis de 14 casos. Med Clin (Barc). 1999 May 1;112(15):577-80.
CLL Trialists’ Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists’ Collaborative Group. J Natl Cancer Inst. 1999 May 19;91(10):861-8.
Terol MJ, López-Guillermo A, Bosch F, Villamor N, Cid MC, Campo E, Montserrat E. Expression of beta-integrin adhesion molecules in non-Hodgkin’s lymphoma: correlation with clinical and evolutive features. J Clin Oncol. 1999 Jun;17(6):1869-75.
Beà S, Ribas M, Hernández JM, Bosch F, Pinyol M, Hernández L, García JL, Flores T, González M, López-Guillermo A, Piris MA, Cardesa A, Montserrat E, Miró R, Campo E. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood. 1999 Jun 15;93(12):4365-74.
Alvarez-Larrán A, López-Guillermo A, Miquel R, Montserrat E. Linfoma T subcutáneo paniculítico. Med Clin (Barc). 1999 Jun 26;113(3):117.
Ferrer A, Cervantes F, Hernández-Boluda JC, Alvarez A, Montserrat E. Leukemoid reaction preceding the diagnosis of colorectal carcinoma by four years. Haematologica. 1999 Jul;84(7):671-2.
Rives S, Carreras E, Rovira M, Montoto S, Urbano-Ispizua A, Martínez C, Perales M, Alvarez A, Esteve J, González M, Montserrat E. Trasplante autogénico de progenitores hemopoyéticos en régimen ambulatorio: análisis de viabilidad en el Hospital Clínic de Barcelona. Med Clin (Barc). 1999 Sep 4;113(6):201-4.
Villamor N, Rozman M, Esteve J, Aymerich M, Colomer D, Aguilar JL, Campo E, Montserrat E. Anaplastic large-cell lymphoma with rapid evolution to leukemic phase. Ann Hematol. 1999 Oct;78(10):478-82.
Cobo F, Hernández S, Hernández L, Pinyol M, Bosch F, Esteve J, López-Guillermo A, Palacín A, Raffeld M, Montserrat E, Jaffe ES, Campo E. Expression of potentially oncogenic HHV-8 genes in an EBV-negative primary effusion lymphoma occurring in an HIV-seronegative patient. J Pathol. 1999 Oct;189(2):288-93.
Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood. 1999 Oct 15;94(8):2836-43.
Zarco MA, Ribera JM, Urbano-Ispizua A, Filella X, Arriols R, Martínez C, Feliu E, Montserrat E. Phenotypic changes in neutrophil granulocytes of healthy donors after G-CSF administration. Haematologica. 1999 Oct;84(10):874-8.
Hernández L, Hernández S, Beà S, Pinyol M, Ferrer A, Bosch F, Nadal A, Fernández PL, Palacín A, Montserrat E, Campo E. c-myc mRNA expression and genomic alterations in mantle cell lymphomas and other nodal non-Hodgkin’s lymphomas. Leukemia. 1999 Dec;13(12):2087-93.
Martínez C, Urbano-Ispizua A, Marín P, Merino A, Rovira M, Carreras E, Montserrat E. Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors. Bone Marrow Transplant. 1999 Dec;24(12):1273-8.

2000

Rafel M, Cervantes F, Beltrán JM, Zuazu F, Hernández Nieto L, Rayón C, García Talavera J, Montserrat E. Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients. Cancer. 2000 Jan 15;88(2):352-7.
Hernández-Boluda JC, Cervantes F, Alvarez A, López-Guillermo A, Montserrat E. Non-Hodgkin’s lymphoma following untreated essential thrombocythemia. Leuk Lymphoma. 2000 Jan;36(3-4):421-3.
Hernández S, Hernández L, Bea S, Pinyol M, Nayach I, Bellosillo B, Nadal A, Ferrer A, Fernández PL, Montserrat E, Cardesa A, Campo E. cdc25a and the splicing variant cdc25b2, but not cdc25B1, -B3 or -C, are over-expressed in aggressive human non-Hodgkin’s lymphomas. Int J Cancer. 2000 Mar 20;89(2):148-52.
Martínez C, Urbano-Ispizua A, Rovira M, Carreras E, Rozman C, Montserrat E. Immune reconstitution following allogeneic peripheral blood progenitor cell transplantation. Leuk Lymphoma. 2000 May;37(5-6):535-42.
Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Cancer. 2000 May 1;88(9):2142-8.
Cervantes F, Hernández-Boluda JC, Alvarez A, Nadal E, Montserrat E. Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica. 2000 Jun;85(6):595-9.
Hernández-Boluda JC, Cervantes F, Costa D, Carrió A, Montserrat E. Blast crisis of Ph-positive chronic myeloid leukemia with isochromosome 17q: report of 12 cases and review of the literature. Leuk Lymphoma. 2000 Jun;38(1-2):83-90.
Montserrat E. Current therapy for CLL. Hematol Cell Ther. 2000 Jun;42(1):31-3.
Pinyol M, Hernández L, Martínez A, Cobo F, Hernández S, Beà S, López-Guillermo A, Nayach I, Palacín A, Nadal A, Fernández PL, Montserrat E, Cardesa A, Campo E. INK4a/ARF locus alterations in human non-Hodgkin’s lymphomas mainly occur in tumors with wild-type p53 gene. Am J Pathol. 2000 Jun;156(6):1987-96.
Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ, Gale RP, Goldman JM, Loberiza FR Jr, Hertenstein B, Klein JP, Montserrat E, Zhang MJ, Ringdén O, Tomany SC, Rowlings PA, Van Hoef ME, Gratwohl A. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2000 Jun 15;95(12):3702-9.
Rives S, Bladé J, Martínez C, Marín P, Carreras E, Montserrat E. Tratamiento con melfalán a altas dosis seguido de rescate con progenitores hematopoyéticos en la amiloidosis primaria. Med Clin (Barc). 2000 Jul 8;115(6):216-20.
Cid J, Revilla M, Cervera A, Cervantes F, Muñoz E, Ferrer I, Montserrat E. Progressive multifocal leukoencephalopathy following oral fludarabine treatment of chronic lymphocytic leukemia. Ann Hematol. 2000 Jul;79(7):392-5.
Cervantes F, Hernández-Boluda JC, Villamor N, Serra A, Montserrat E. Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis. Eur J Haematol. 2000 Aug;65(2):104-8.
Cervantes F, Rovira M, Urbano-Ispizua A, Rozman M, Carreras E, Montserrat E. Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect. Bone Marrow Transplant. 2000 Sep;26(6):697-9.
Martínez C, Carreras E, Rovira M, Urbano-Ispizua A, Esteve J, Perales M, Fernández F, Montserrat E. Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation. Bone Marrow Transplant. 2000 Sep;26(6):677-9.
Bladé J, Esteve J, Rives S, Martínez C, Rovira M, Urbano-Ispizua A, Marín P, Carreras E, Montserrat E. High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution. Bone Marrow Transplant. 2000 Oct;26(8):845-9.
Villamor N, Costa D, Aymerich M, Esteve J, Carrió A, Rozman M, Aguilar JL, Falini B, Montserrat E, Campo E, Colomer D. Rapid diagnosis of acute promyelocytic leukemia by analyzing the immunocytochemical pattern of the PML protein with the monoclonal antibody PG-M3. Am J Clin Pathol. 2000 Nov;114(5):786-92.

2001

Montserrat E. Developing risk-adapted treatment strategies for chronic lymphocytic leukemia. In: Cheson B, ed. Chronic Lymphocytic Leukemia. 2^nd ed. New York, NY: Marcel Dekker; 2001: 377-391.
Sierra J, Muñoz L, Rovira M, Canals C, Ortega JJ, Olivé T, Badell I, Julià A, Carreras E, Brunet S, Ribera JM, Montserrat E. Hematopoietic stem cell transplantation as a treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia. In: Dicke KA, Keating A, eds. Autologous Blood and Marrow Transplantation. 10th ed. Charlottesville, VA: Carden Jennings; 2001: 372-379.
Müller-Hermelink HK, Catovsky D, Montserrat E, Harris NL. Chronic lymphocytic leukaemia/small lymphocytic leukaemia. In Jaffe E, Harris NL, Stein H, Vardiman JW, Eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:127-130.
Catovsky D, Montserrat E, Müller-Hermelink HK, Harris NL. B-cell prolymphocytic leukaemia. In Jaffe E, Harris NL, Stein H, Vardiman JW, Eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:131-134.
Isaacson PG, Piris MA, Catovsky D, Swerdlow S, Montserrat E, Berger F, Müller-Hermelink HK, Nathwani B, Harris NL. Splenic marginal zone lymphoma. In Jaffe E, Harris NL, Stein H, Vardiman JW, Eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:135-136.
Chan WC, Catovsky D, Foucar K, Montserrat E. T-cell large granular lymphocyte leukaemia. In Jaffe E, Harris NL, Stein H, Vardiman JW, Eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:197-198.
Bladé J, San Miguel JF, Fontanillas M, Esteve J, Maldonado J, Alcalá A, Brunet S, García-Conde J, Besalduch J, Moro MJ, Fernández-Calvo J, Conde E, Font L, Gardella S, Carnero M, Carbonell F, Martí JM, Hernández-Martín J, Ortega F, Besses C, Ribera JM, Trujillo J, Escudero ML, Rozman C, Estapé J, Montserrat E. Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. Hematol J. 2001;2(4):272-8.
Rai KR, Döhner H, Keating MJ, Montserrat E. Chronic lymphocytic leukemia: case-based session. Hematology Am Soc Hematol Educ Program. 2001:140-56.
Urbano-Ispizua A, Rozman C, Pimentel P, Solano C, de la Rubia J, Brunet S, Pérez-Oteiza J, Ferrá C, Zuazu J, Caballero D, Carvalhais A, Díez JL, Espigado I, Martínez C, Campilho F, Sanz MA, Sierra J, García-Conde J, Montserrat E. The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings. Blood. 2001 Jan 15;97(2):383-7.
Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO, Pavlovsky S, Keating A, Yanes B, van Besien K, Armitage JO, Horowitz MM; Autologous Blood and Marrow Transplant Registry Lymphoma Working Committee. Autologous transplantation for diffuse aggressive non-Hodgkin’s lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2001 Jan 15;19(2):406-13.
Sanz-Vaqué L, Colomer D, Bosch F, López-Guillermo A, Dreyling MH, Bosch F, Montserrat E, Campo E. Microsatellite instability analysis in typical and progressed mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Haematologica. 2001 Feb;86(2):181-6.
Nadal E, Cervantes F, Rosiñol L, Talarn C, Montserrat E. Hypercalcemia as the presenting feature of t-cell lymphoid blast crisis of ph-positive chronic myeloid leukemia. Leuk Lymphoma. 2001 Mar;41(1-2):203-6.
Esteve J, Villamor N, Colomer D, Cervantes F, Campo E, Carreras E, Montserrat E. Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia. 2001 Mar;15(3):445-51.
Villela L, López-Guillermo A, Montoto S, Rives S, Bosch F, Perales M, Ferrer A, Esteve J, Colomo L, Campo E, Montserrat E. Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. Cancer. 2001 Apr 15;91(8):1557-62.
Martínez C, Carreras E, Rovira M, Urbano-Ispizua A, Esteve J, Fernández-Avilés F, Perales M, Rives S, Gómez M, Montserrat E. Allogenic stem cell transplantation as salvage therapy for patients relapsing after autologous transplantation: experience from a single institution. Leuk Res. 2001 May;25(5):379-84.
Bladé J, Perales M, Rosiñol L, Tuset M, Montoto S, Esteve J, Cobo F, Villela L, Rafel M, Nomdedeu B, Montserrat E. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Br J Haematol. 2001 May;113(2):422-4.
Cervantes F, Barosi G, Hernández-Boluda JC, Marchetti M, Montserrat E. Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival. Eur J Haematol. 2001 May;66(5):324-7.
Ferrer A, López-Guillermo A, Montoto S, Estrach T, Colomo L, Montserrat E. Successful treatment of isolated cutaneous relapse of follicular lymphoma with rituximab. Ann Hematol. 2001 Aug;80(8):479-81.
Urbano-Ispizua A, Brunet S, Solano C, Moraleda JM, Rovira M, Zuazu J, de La Rubia J, Bargay J, Caballero D, Díez-Martín JL, Ojeda E, Pérez de Oteiza JP, Ferrá C, Espigado I, Alegre A, de La Serna J, Torres P, Riu C, Odriozola J, Rozman C, Sierra J, García-Conde J, Montserrat E. Allogeneic transplantation of CD34+-selected cells from peripheral blood in patients with myeloid malignancies in early phase: a case control comparison with unmodified peripheral blood transplantation. Bone Marrow Transplant. 2001 Aug;28(4):349-54.
Hernández-Boluda JC, Cervantes F, Alvarez A, Costa D, Montserrat E. Single-agent therapy with oral mercaptopurine for nonlymphoid blast crisis of chronic myeloid leukemia. Ann Hematol. 2001 Sep;80(9):516-20.
Urbano-Ispizua A, Carreras E, Marín P, Rovira M, Martínez C, Fernández-Avilés F, Xicoy B, Hernández-Boluda JC, Montserrat E. Allogeneic transplantation of CD34(+) selected cells from peripheral blood from human leukocyte antigen-identical siblings: detrimental effect of a high number of donor CD34(+) cells? Blood. 2001 Oct 15;98(8):2352-7.
Montserrat E. Prognostic factors in aggressive lymphoma: the contribution of novel biological markers. Ann Hematol. 2001 Nov;80(Suppl 3):B42-4.
Bellosillo B, Villamor N, López-Guillermo A, Marcé S, Esteve J, Campo E, Colomer D, Montserrat E. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood. 2001 Nov 1;98(9):2771-7.
Rovira M, Carreras E, Bladé J, Graus F, Valls J, Fernández-Avilés F, Montserrat E. Dramatic improvement of POEMS syndrome following autologous haematopoietic cell transplantation. Br J Haematol. 2001 Nov;115(2):373-5.
Cervantes F, Sureda A, Hernández-Boluda JC, Martino R, Brunet S, Borrego D, Antich JL, Montserrat E. Interferon alpha plus intermittent oral Ara-C ocfosfate (YNK-01) in chronic myeloid leukemia primarily resistant or with minimal cytogenetic response to interferon. Haematologica. 2001 Dec;86(12):1281-6.
Bladé J, Esteve J, Rosiñol L, Perales M, Montoto S, Tuset M, Montserrat E. Thalidomide in refractory and relapsing multiple myeloma. Semin Oncol. 2001 Dec;28(6):588-92.

2002

Camacho E, Hernández L, Hernández S, Tort F, Bellosillo B, Beà S, Bosch F, Montserrat E, Cardesa A, Fernández PL, Campo E. ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. Blood. 2002;99(1):238-244.
Montserrat E. Classical and new prognostic factors in chronic lymphocytic leukemia: where to now? Hematol J. 2002;3(1):7-9.
Hernández-Boluda JC, Carreras E, Cervantes F, Marín P, Arellano-Rodrigo E, Rovira M, Solé F, Lloveras E, Espinet B, Ocejo A, Montserrat E. Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-interferon. Haematologica. 2002 Jan;87(1):17-22.
Jiménez-Hernández M, López-Guillermo A, Cobo F, Bladé J, Aguilar JL, Villamor N, Montserrat E. Bladder involvement of diffuse large B-cell lymphoma diagnosed by a cytological study of the urine. Leuk Lymphoma. 2002 Jan;43(1):187-9.
Bessell EM, López-Guillermo A, Villá S, Verger E, Nomdedeu B, Petit J, Byrne P, Montserrat E, Graus F. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol. 2002 Jan 1;20(1):231-6.
Fend F, Martinez A, Quintanilla-Martinez L, Sanz L, Combalia N, Raffeld M, Jaffe ES, Montserrat E, Campo E. Clonally unrelated Hodgkin’s disease following autologous stem cell transplant for B-cell lymphoma. Br J Haematol. 2002 Feb;116(2):329-33.
Esteve J, Villamor N, Colomer D, Montserrat E. Different clinical value of minimal residual disease after autologous and allogenic stem cell transplantation for chronic lymphocytic leukemia. Blood. 2002 Mar 1;99(5):1873-4.
Montoto S, López-Guillermo A, Ferrer A, Camós M, Alvarez-Larrán A, Bosch F, Bladé J, Cervantes F, Esteve J, Cobo F, Colomer D, Campo E, Montserrat E. Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. Ann Oncol. 2002 Apr;13(4):523-30.
Bladé J, Filella X, Montoto S, Bosch F, Rosiñol L, Coca F, Giné E, Nadal E, Aymerich M, Rozman M, Montserrat E. Interleukin 6 and tumour necrosis factor alpha serum levels in monoclonal gammopathy of undetermined significance. Br J Haematol. 2002 May;117(2):387-9.
Cobo F, Martínez A, Pinyol M, Hernández L, Gómez M, Beá S, Esteve J, Rozman M, Bosch F, López-Guillermo A, Montserrat E, Campo E. Multiple cell cycle regulator alterations in Richter’s transformation of chronic lymphocytic leukemia. Leukemia. 2002 Jun;16(6):1028-34.
Dreger P, Montserrat E. Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia. 2002 Jun;16(6):985-92.
Montserrat E. Prognosis in chronic lymphocytic leukemia: let’s have a look! Haematologica. 2002 Jun;87(6):561-2.
Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jun 20;346(25):1937-47.
Montoto S, Bladé J, Montserrat E. Monoclonal gammopathy of undetermined significance. N Engl J Med. 2002 Jun 27;346(26):2087-8.
Urbano-Ispizua A, Rozman C, Pimentel P, Solano C, de la Rubia J, Brunet S, Pérez-Oteyza J, Ferrá C, Zuazu J, Caballero D, Bargay J, Carvalhais A, Díez JL, Espigado I, Alegre A, Rovira M, Campilho F, Odriozola J, Sanz MA, Sierra J, García-Conde J, Montserrat E. Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. Blood. 2002 Jul 15;100(2):724-7.
Altès A, Sierra J, Esteve J, Martín-Henao G, Marín P, Sureda A, Briones J, Martino R, Villamor N, Colomer D, Carreras E, Garcia J, Brunet S, Montserrat E. CD34+-enriched-CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders: high purging efficiency but increased risk of severe infections. Exp Hematol. 2002 Jul;30(7):824-30.
Giné E, Bosch F, Villamor N, Rozman M, Colomer D, López-Guillermo A, Campo E, Montserrat E. Simultaneous diagnosis of hairy cell leukemia and chronic lymphocytic leukemia/small lymphocytic lymphoma: a frequent association? Leukemia. 2002 Aug;16(8):1454-9.
Bellosillo B, Villamor N, López-Guillermo A, Marcé S, Bosch F, Campo E, Montserrat E, Colomer D. Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. Blood. 2002 Sep 1;100(5):1810-6.
Montserrat E. Current and developing chemotherapy for CLL. Med Oncol. 2002;19(Suppl 2):S11-9.
Beà S, López-Guillermo A, Ribas M, Puig X, Pinyol M, Carrió A, Zamora L, Soler F, Bosch F, Stilgenbauer S, Colomer D, Miró R, Montserrat E, Campo E. Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter’s syndrome). Am J Pathol. 2002 Sep;161(3):957-68.
Cervantes F, Alvarez-Larrán A, Talarn C, Gómez M, Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol. 2002 Sep;118(3):786-90.
Salar A, Martino R, Perea G, Ribera JM, López-Guillermo A, Guardia R, Escoda L, Altés A, Sierra J, Montserrat E. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin’s lymphoma. Haematologica. 2002 Oct;87(10):1028-35.
Gratwohl A, Baldomero H, Horisberger B, Schmid C, Passweg J, Urbano-Ispizua A; Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT). Current trends in hematopoietic stem cell transplantation in Europe. Blood. 2002 Oct 1;100(7):2374-86.
Cobo F, Rosiñol L, Martínez A, Martín F, Esteve J, Gómez M, Nadal E, Bosch F, Javier Setoain F, Campo E, Montserrat E. Limitations of Gallium-67 SPECT in histological transformation of chronic lymphocytic leukaemia: an analysis of 13 patients with clinically suspected Richter’s syndrome. Br J Haematol. 2002 Nov;119(2):484-7.
Fouillard L, Labopin M, Gratwohl A, Powles R, Bacigalupo A, Bego G, Chesnel V, Gorin NC; European Group for Blood and Marrow Transplantation (EBMT). Outcome of 5651 hematopoietic stem cell transplants for hematological malignancies carried out in Europe in 1993: a reliability study of the registry. Bone Marrow Transplant. 2002 Nov;30(10):637-43.
Arellano-Rodrigo E, Rovira M, Cibeira MT, Abelló D, Montserrat E. Fingertip cellulitis after fingerstick for capillary microhematocrit measurement in a patient with chronic lymphocytic leukemia: an uncommon infectious complication. Haematologica. 2002 Dec;87(12):ECR39.
Bosch F, Ferrer A, López-Guillermo A, Giné E, Bellosillo B, Villamor N, Colomer D, Cobo F, Perales M, Esteve J, Altés A, Besalduch J, Ribera JM, Montserrat E. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol. 2002 Dec;119(4):976-84.
Bosch F, Montserrat E. Refining prognostic factors in chronic lymphocytic leukemia. Rev Clin Exp Hematol. 2002 Dec;6(4):335-49.
Gratwohl A, Brand R, Apperley J, Biezen Av Av, Bandini G, Devergie A, Schattenberg A, Frassoni F, Guglielmi C, Iacobelli S, Michallet M, Kolb HJ, Ruutu T, Niederwieser D; Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (CLWP-EBMT). Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood. 2002 Dec 1;100(12):3877-86.
Gratwohl A, Baldomero H, Passweg J, Urbano-Ispizua A; European Group for Blood and Marrow Transplantation (EBMT). Accreditation Committee. Increasing use of reduced intensity conditioning transplants: report of the 2001 EBMT activity survey. Bone Marrow Transplant. 2002 Dec;30(12):813-31.

2003

Colomo L, López-Guillermo A, Perales M, Rives S, Martínez A, Bosch F, Colomer D, Falini B, Montserrat E, Campo E. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood. 2003 Jan 1;101(1):78-84. Epub 2002 Aug 8.
Montoto S, López-Guillermo A, Colomer D, Esteve J, Bosch F, Ferrer A, Villamor N, Moreno C, Campo E, Montserrat E. Incidence and clinical significance of bcl-2/IgH rearrangements in follicular lymphoma. Leuk Lymphoma. 2003 Jan;44(1):71-6.
Montserrat E. Rituximab in chronic lymphocytic leukemia. Semin Oncol. 2003 Feb;30(1S2):34-39.
Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Fisher RI, Miller TP, LeBlanc M, Ott G, Kvaloy S, Holte H, Delabie J, Staudt LM. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003 Feb;3(2):185-97.
Cibeira MT, Lopez-Guillermo A, Colomer D, Ricart MJ, Alcaraz A, Martinez A, Campo E, Montserrat E. Diffuse large B-cell lymphoma arising from donor lymphoid cells after renal and pancreatic transplantation. Ann Hematol. 2003 Feb;82(2):131-135. Epub 2003 Feb 11.
Cervantes F, Hernández-Boluda JC, Odriozola J, Camós M, Villalón L, Martínez-Climent JA, del Campo R, García-Conde J, Montserrat E. Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation. Br J Haematol. 2003 Feb;120(3):500-4.
Molina-Arcas M, Bellosillo B, Casado FJ, Montserrat E, Gil J, Colomer D, Pastor-Anglada M. Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. Blood. 2003 Mar 15;101(6):2328-34. Epub 2002 Oct 31.
Carreras E, Saiz A, Marín P, Martínez C, Rovira M, Villamor N, Aymerich M, Lozano M, Fernández-Avilés F, Urbano-Izpizua A, Montserrat E, Graus F. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. Haematologica. 2003 Mar;88(3):306-14.
Fernández-Avilés F, Urbano-Ispizua A, Aymerich M, Colomer D, Rovira M, Martínez C, Nadal E, Talarn C, Carreras E, Montserrat E. Serial quantification of lymphoid and myeloid mixed chimerism using multiplex PCR amplification of short tandem repeat-markers predicts graft rejection and relapse, respectively, after allogeneic transplantation of CD34+ selected cells from peripheral blood. Leukemia. 2003 Mar;17(3):613-20.
Hernández-Boluda JC, Cervantes F, Colomer D, Vela MC, Costa D, Paz MF, Esteller M, Montserrat E. Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis: a sequential study in 42 patients. Exp Hematol. 2003 Mar;31(3):204-10.
Arellano-Rodrigo E, López-Guillermo A, Bessell EM, Nomdedeu B, Montserrat E, Graus F. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol. 2003 Apr;70(4):219-24.
Montoto S, Rozman M, Rosiñol L, Nadal E, Giné E, Aymerich M, Ferrer A, Esteve J, Bosch F, López-Guillermo A, Bladé J, Montserrat E. Malignant transformation in IgM monoclonal gammopathy of undetermined significance. Semin Oncol. 2003 Apr;30(2):178-81.
Bladé J, Montoto S, Rosiñol L, Montserrat E. Appropriateness of applying the response criteria for multiple myeloma to Waldenstrom’s macroglobulinemia? Semin Oncol. 2003 Apr;30(2):329-31.
Zucca E, Conconi A, Pedrinis E, Cortelazzo S, Motta T, Gospodarowicz MK, Patterson BJ, Ferreri AJ, Ponzoni M, Devizzi L, Giardini R, Pinotti G, Capella C, Zinzani PL, Pileri S, López-Guillermo A, Campo E, Ambrosetti A, Baldini L, Cavalli F; International Extranodal Lymphoma Study Group. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003 Apr 1;101(7):2489-95. Epub 2002 Nov 27.
Cobo F, Quinto LL, Rozman M, Costa D, Puigoriol E, Arellano E, Villela L, Montserrat E, Campo E, Nomdedeu B. Analysis of 178 myelodysplastic syndrome patients: validation of the World Health Organization classification and the International Prognostic Scoring System. Leuk Res. 2003 May;27(Suppl 1):18-19.
Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marcé S, López-Guillermo A, Campo E, Montserrat E. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003 May 1;348(18):1764-75.
Giné E, Rovira M, Real I, Burrel M, Montaña J, Carreras E, Montserrat E. Successful treatment of severe hemorrhagic cystitis after hemopoietic cell transplantation by selective embolization of the vesical arteries. Bone Marrow Transplant. 2003 May;31(10):923-5.
Perea G, Altés A, Montoto S, López-Guillermo A, Bosch F, Jiménez M, Esteve J, Domingo E, Ribera JM, Pedro C, Martino R, Briones J, Sureda A, Brunet S, Sierra J, Montserrat E. International and Italian prognostic indices in follicular lymphoma. Haematologica. 2003 Jun;88(6):700-4.
Villamor N, Montserrat E, Colomer D. Mechanism of action and resistance to monoclonal antibody therapy. Semin Oncol. 2003 Aug;30(4):424-33. https://doi.org/10.1016/S0093-7754(03)00261-6
Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, Lopez-Guillermo A, Ott G, Muller-Hermelink HK, Connors JM, Braziel R, Grogan TM, Fisher RI, Miller TP, LeBlanc M, Chiorazzi M, Zhao H, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Staudt LM. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003 Sep 15;198(6):851-62.
Fernández-Avilés F, Urbano-Ispizua A, Aymerich M, Rovira M, Martínez C, Talarn C, Jiménez M, Carreras E, Montserrat E. Low-dose total-body irradiation and fludarabine followed by hematopoietic cell transplantation from HLA-identical sibling donors do not induce complete T-cell donor engraftment in most patients with progressive hematologic diseases. Exp Hematol. 2003 Oct;31(10):934-40.
Costa D, Queralt R, Aymerich M, Carrió A, Rozman M, Vallespí T, Colomer D, Nomdedeu B, Montserrat E, Campo E. High levels of chromosomal imbalances in typical and small-cell variants of T-cell prolymphocytic leukemia. Cancer Genet Cytogenet. 2003 Nov;147(1):36-43.
Rosiñol L, Bladé J, Esteve J, Aymerich M, Rozman M, Montoto S, Giné E, Nadal E, Filella X, Queralt R, Carrió A, Montserrat E. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol. 2003 Nov;123(4):631-6.
Schetelig J, Fetscher S, Reichle A, Berdel WE, Beguin Y, Brunet S, Caballero D, Majolino I, Hagberg H, Johnsen HE, Kimby E, Montserrat E, Stewart D, Copplestone A, Rösler W, Pavel J, Kingreen D, Siegert W. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica. 2003 Nov;88(11):1272-8.

2004

Bosch F, Montserrat E. Prognostic indicators of chronic lymphocytic leukemia. In Faguet GB, ed. Chronic Lymphocytic Leukemia: Molecular Genetics, Biology, Diagnosis, and Management. Totowa, NJ: Humana Press Inc. 2004; 201-215.
Montserrat E. Treatment options in chronic lymphocytic leukemia. Hematol J. 2004;5(Suppl 1):S2-9.
Villamor N, Montserrat E, Colomer D. Cytotoxic effects of B lymphocytes mediated by reactive oxygen species. Curr Pharm Des. 2004;10(8):841-53.
Nadal E, Giné E, Bladé J, Esteve J, Rosiñol L, Fernández-Avilés F, Marin P, Martinez C, Rovira M, Urbano-Ispizua A, Carreras E, Montserrat E. High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission. Bone Marrow Transplant. 2004 Jan;33(1):61-4.
Camós M, Esteve J, Rimola A, Grande L, Rozman M, Colomer D, Villamor N, Costa D, Montserrat E. Increased incidence of acute myeloid leukemia after liver transplantation? Description of three new cases and review of the literature. Transplantation. 2004 Jan 27;77(2):311-3.
Martinez A, Bellosillo B, Bosch F, Ferrer A, Marcé S, Villamor N, Ott G, Montserrat E, Campo E, Colomer D. Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol. 2004 Feb;164(2):501-10.
Tort F, Camacho E, Bosch F, Harris NL, Montserrat E, Campo E. Familial lymphoid neoplasms in patients with mantle cell lymphoma. Haematologica. 2004 Mar;89(3):314-9.
Montserrat E. Monoclonal antibodies in the treatment of chronic lymphocytic leukemia: if only it were simple. Blood. 2004 Mar 1;103(5):1567-1568.
Rovira M, Jimenéz M, De La Bellacasa JP, Mensa J, Rafel M, Ortega M, Almela M, Martínez C, Fernández-Avilés F, Martínez JA, Urbano-Ispizua A, Carreras E, Montserrat E. Detection of Aspergillus galactomannan by enzyme immunoabsorbent assay in recipients of allogeneic hematopoietic stem cell transplantation: a prospective study. Transplantation. 2004 Apr 27;77(8):1260-4.
Rosiñol L, Cibeira MT, Segarra M, Cid MC, Filella X, Aymerich M, Rozman M, Arenillas L, Esteve J, Bladé J, Montserrat E. Response to thalidomide in multiple myeloma: impact of angiogenic factors. Cytokine. 2004 May 21;26(4):145-8.
Passweg JR, Walker I, Sobocinski KA, Klein JP, Horowitz MM, Giralt SA; Chronic Leukemia Study Writing Committee of the International Bone Marrow Transplant Registry. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol. 2004 Jun;125(5):613-20.
Rozman M, Camós M, Colomer D, Villamor N, Esteve J, Costa D, Carrió A, Aymerich M, Aguilar JL, Domingo A, Solé F, Gomis F, Florensa L, Montserrat E, Campo E. Type I MOZ/CBP (MYST3/CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation. Genes Chromosomes Cancer. 2004 Jun;40(2):140-5.
Martinez A, Pittaluga S, Villamor N, Colomer D, Rozman M, Raffeld M, Montserrat E, Campo E, Jaffe ES. Clonal T-cell populations and increased risk for cytotoxic T-cell lymphomas in B-CLL patients: clinicopathologic observations and molecular analysis. Am J Surg Pathol. 2004 Jul;28(7):849-58.
Oriol A, Ribera JM, Esteve J, Guàrdia R, Brunet S, Bueno J, Pedro C, Llorente A, Tormo M, Besalduch J, Sánchez JM, Batlle M, Vivancos P, Carreras E, Vilà JM, Julià A, Sierra J, Montserrat E, Feliu E. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol. Haematologica. 2004 Jul;89(7):791-800.
Rosiñol L, Cibeira MT, Bladé J, Esteve J, Aymerich M, Rozman M, Segarra M, Cid MC, Filella X, Montserrat E. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica. 2004 Jul;89(7):832-6.
Montserrat E. Role of auto- and allotransplantation in B-cell chronic lymphocytic leukemia. Hematol Oncol Clin North Am. 2004 Aug;18(4):915-26.
Brunet S, Esteve J, Berlanga J, Ribera JM, Bueno J, Martí JM, Bargay J, Guardia R, Juliá A, Granena A, Montserrat E, Sierra J. Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy. Haematologica. 2004 Aug;89(8):940-9.
Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haïoun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E. Follicular lymphoma international prognostic index. Blood. 2004 Sep 1;104(5):1258-65. Epub 2004 May 4.
Beà S, Colomo L, López-Guillermo A, Salaverria I, Puig X, Pinyol M, Rives S, Montserrat E, Campo E. Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-cell lymphomas. J Clin Oncol. 2004 Sep 1;22(17):3498-506.
Montserrat E. Assessing prognosis in patients with chronic lymphocytic leukemia a quarter of a century after Rai and Binet staging systems. Ann Oncol. 2004 Oct;15(10):1450-1.
Montoto S, López-Guillermo A, Altés A, Perea G, Ferrer A, Camós M, Villela L, Bosch F, Esteve J, Cervantes F, Bladé J, Nomdedeu B, Campo E, Sierra J, Montserrat E. Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol. 2004 Oct;15(10):1484-9.
Eisterer W, Bechter O, Söderberg O, Nilsson K, Terol M, Greil R, Thaler J, Herold M, Finke L, Günthert U, Montserrat E, Stauder R. Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia. Leuk Res. 2004 Oct;28(10):1043-51.
Ferrer A, Marcé S, Bellosillo B, Villamor N, Bosch F, López-Guillermo A, Espinet B, Solé F, Montserrat E, Campo E, Colomer D. Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes. Oncogene. 2004 Nov 25;23(55):8941-9.
Cervantes F, Alvarez-Larrán A, Hernández-Boluda JC, Sureda A, Torrebadell M, Montserrat E. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol. 2004 Nov;127(4):399-403.
Fernàndez V, Jares P, Beà S, Salaverria I, Guino E, de Sanjosé S, Colomer D, Ott G, Montserrat E, Campo E. Frequent polymorphic changes but not mutations of TRAIL receptors DR4 and DR5 in mantle cell lymphoma and other B-cell lymphoid neoplasms. Haematologica. 2004 Nov;89(11):1322-31.
Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M, Staudt LM. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004 Nov 18;351(21):2159-69.

2005

Molina-Arcas M, Marcé S, Villamor N, Huber-Ruano I, Casado FJ, Bellosillo B, Montserrat E, Gil J, Colomer D, Pastor-Anglada M. Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells. Leukemia. 2005 Jan;19(1):64-8.
Montserrat E. CLL therapy: progress at last! Blood. 2005 Jan 1; 105(1):2-3.
Ghia P, Stamatopoulos K, Belessi C, Moreno C, Stella S, Guida G, Michel A, Crespo M, Laoutaris N, Montserrat E, Anagnostopoulos A, Dighiero G, Fassas A, Caligaris-Cappio F, Davi F. Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood. 2005 Feb 15;105(4):1678-85. Epub 2004 Oct 5.
Carreras J, Villamor N, Colomo L, Moreno C, Ramón y Cajal S, Crespo M, Tort F, Bosch F, López-Guillermo A, Colomer D, Montserrat E, Campo E. Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. J Pathol. 2005 Mar;205(4):507-13.
Montillo M, Hamblin T, Hallek M, Montserrat E, Morra E. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica. 2005 Mar;90(3):391-9.
Hernández L, Beà S, Pinyol M, Ott G, Katzenberger T, Rosenwald A, Bosch F, López-Guillermo A, Delabie J, Colomer D, Montserrat E, Campo E. CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. Cancer Res. 2005 Mar 15;65(6):2199-206.
López-Guillermo A, Colomo L, Jiménez M, Bosch F, Villamor N, Arenillas L, Muntañola A, Montoto S, Giné E, Colomer D, Beà S, Campo E, Montserrat E. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol. 2005 Apr 20;23(12):2797-804. Epub 2005 Feb 22.
Montserrat E. Treatment of chronic lymphocytic leukemia: achieving minimal residual disease-negative status as a goal. J Clin Oncol. 2005 May 1;23(13):2884-5. Epub 2005 Feb 28.
Moreno C, Villamor N, Colomer D, Esteve J, Martino R, Nomdedéu J, Bosch F, López-Guillermo A, Campo E, Sierra J, Montserrat E. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol. 2005 May 20;23(15):3433-8. Epub 2005 Apr 4.
Cervantes F, Alvarez-Larrán A, Domingo A, Arellano-Rodrigo E, Montserrat E. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol. 2005 Jun;129(6):771-5.
Pavletic SZ, Khouri IF, Haagenson M, King RJ, Bierman PJ, Bishop MR, Carston M, Giralt S, Molina A, Copelan EA, Ringdén O, Roy V, Ballen K, Adkins DR, McCarthy P, Weisdorf D, Montserrat E, Anasetti C. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research. J Clin Oncol. 2005 Aug 20;23(24):5788-94. Epub 2005 Jul 25.
Monill J, Pernas J, Montserrat E, Pérez C, Clavero J, Martinez-Noguera A, Guerrero R, Torrubia S. CT features of abdominal plasma cell neoplasms. Eur Radiol. 2005 Aug;15(8):1705-12. Epub 2005 Jan 27.
Perea G, Altés A, Montoto S, López-Guillermo A, Domingo-Doménech E, Fernández-Sevilla A, Ribera JM, Grau J, Pedro C, Angel Hernández J, Estany C, Briones J, Martino R, Sureda A, Sierra J, Montserrat E. Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. Ann Oncol. 2005 Sep;16(9):1508-13. Epub 2005 Jun 6.
Rosiñol L, Carrió A, Bladé J, Queralt R, Aymerich M, Cibeira MT, Esteve J, Rozman M, Campo E, Montserrat E. Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma. Br J Haematol. 2005 Sep;130(5):729-32.
Jiménez M, Martínez C, Ercilla G, Carreras E, Urbano-Ispízua A, Aymerich M, Villamor N, Amézaga N, Rovira M, Fernández-Avilés F, Gaya A, Martino R, Sierra J, Montserrat E. Reduced-intensity conditioning regimen preserves thymic function in the early period after hematopoietic stem cell transplantation. Exp Hematol. 2005 Oct;33(10):1240-8.
Montserrat E. Fighting CLL cells: deciphering the enemy. Blood. 2005 Oct 1; 106(7):2226.
Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, Burek C, Ott G, Puig X, Yang L, Lopez-Guillermo A, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Gascoyne RD, Connors JM, Grogan TM, Braziel R, Fisher RI, Smeland EB, Kvaloy S, Holte H, Delabie J, Simon R, Powell J, Wilson WH, Jaffe ES, Montserrat E, Muller-Hermelink HK, Staudt LM, Campo E, Rosenwald A. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005 Nov 1;106(9):3183-90. Epub 2005 Jul 26.
Moreno C, Montserrat E. In reply: Chronic lymphocytic leukemia: to transplant or not to transplant…that is the question? J Clin Oncol. 2005 Nov 1;23(31):8127–8128.

2006

Montserrat E. New prognostic markers in CLL. Hematology Am Soc Hematol Educ Program. 2006:279-84.
Pérez-Galán P, Roué G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006 Jan 1;107(1):257-64. Epub 2005 Sep 15.
Plancarte F, López-Guillermo A, Arenillas L, Montoto S, Giné E, Muntañola A, Ferrer A, Villamor N, Bosch F, Colomo L, Balaguer O, Campo E, Montserrat E. Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. Eur J Haematol. 2006 Jan;76(1):58-63.
Cervantes F, Alvarez-Larrán A, Arellano-Rodrigo E, Granell M, Domingo A, Montserrat E. Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution. Leukemia. 2006 Jan;20(1):55-60.
Montserrat E, Moreno C, Esteve J, Urbano-Ispizua A, Giné E, Bosch F. How I treat refractory CLL. Blood. 2006 Feb 15;107(4):1276-83. Epub 2005 Oct 4.
Binet JL, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G, Döhner H, Hallek M, Hillmen P, Keating M, Montserrat E, Kipps TJ, Rai K. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood. 2006 Feb 1;107(3):859-61. Epub 2005 Oct 13.
Crespo M, Villamor N, Giné E, Muntañola A, Colomer D, Marafioti T, Jones M, Camós M, Campo E, Montserrat E, Bosch F. ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):726-34.
Rosiñol L, Cibeira MT, Uriburu C, Yantorno S, Salamero O, Bladé J, Montserrat E. Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol. 2006 May;76(5):405-8. Epub 2006 Mar 9.
Talarn C, Urbano-Ispizua A, Martino R, Batlle M, Fernández-Avilés F, Herrera C, Pérez-Simón JA, Gaya A, Aymerich M, Pétriz J, Marín P, Sierra J, Montserrat E. G-CSF increases the number of peripheral blood dendritic cells CD16+ and modifies the expression of the costimulatory molecule CD86+. Bone Marrow Transplant. 2006 May;37(9):873-9.
Moreno C, Villamor N, Colomer D, Esteve J, Giné E, Muntañola A, Campo E, Bosch F, Montserrat E. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood. 2006 Jun 1;107(11):4563-9. Epub 2006 Jan 31.
Monzo M, Brunet S, Urbano-Ispizua A, Navarro A, Perea G, Esteve J, Artells R, Granell M, Berlanga J, Ribera JM, Bueno J, Llorente A, Guardia R, Tormo M, Torres P, Nomdedéu JF, Montserrat E, Sierra J. Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Blood. 2006 Jun 15;107(12):4871-9. Epub 2006 Feb 28.
Jiménez M, Martínez C, Ercilla G, Carreras E, Urbano-Ispízua A, Aymerich M, Villamor N, Amézaga N, Rovira M, Fernández-Avilés F, Montserrat E. Clinical factors influencing T-cell receptor excision circle (TRECs) counts following allogeneic stem cell transplantation in adults. Transpl Immunol. 2006 Jun;16(1):52-9. Epub 2006 Mar 31.
Marcé S, Balagué O, Colomo L, Martinez A, Höller S, Villamor N, Bosch F, Ott G, Rosenwald A, Leoni L, Esteller M, Fraga MF, Montserrat E, Colomer D, Campo E. Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy. Clin Cancer Res. 2006 Jun 15;12(12):3754-61.
Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006 Jun 8;354(23):2431-42.
Cervantes F, Alvarez-Larrán A, Hernández-Boluda JC, Sureda A, Granell M, Vallansot R, Besses C, Montserrat E. Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia. Br J Haematol. 2006 Jul;134(2):184-6. Epub 2006 Jun 1.
Belessi CJ, Davi FB, Stamatopoulos KE, Degano M, Andreou TM, Moreno C, Merle-Béral H, Crespo M, Laoutaris NP, Montserrat E, Caligaris-Cappio F, Anagnostopoulos AZ, Ghia P. IGHV gene insertions and deletions in chronic lymphocytic leukemia: “CLL-biased” deletions in a subset of cases with stereotyped receptors. Eur J Immunol. 2006 Jul;36(7):1963-74.
Camós M, Esteve J, Jares P, Colomer D, Rozman M, Villamor N, Costa D, Carrió A, Nomdedéu J, Montserrat E, Campo E. Gene expression profiling of acute myeloid leukemia with translocation t(8;16)(p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression. Cancer Res. 2006 Jul 15;66(14):6947-54.
Bosch F, Muntañola A, Giné E, Carrió A, Villamor N, Moreno C, Crespo M, Montserrat E. Clinical implications of ZAP-70 expression in chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2006 Jul 15;70(4):214-7.
Granell M, Urbano-Ispizua A, Suarez B, Rovira M, Fernández-Avilés F, Martínez C, Ortega M, Uriburu C, Gaya A, Roncero JM, Navarro A, Carreras E, Mensa J, Vives J, Rozman C, Montserrat E, Lozano F. Mannan-binding lectin pathway deficiencies and invasive fungal infections following allogeneic stem cell transplantation. Exp Hematol. 2006 Oct;34(10):1435-41.
Fernández-Avilés F, Carreras E, Urbano-Ispizua A, Rovira M, Martínez C, Gaya A, Granell M, Ramiro L, Gallego C, Hernando A, Segura S, García L, González M, Valverde M, Montserrat E. Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies. J Clin Oncol. 2006 Oct 20;24(30):4855-61. Epub 2006 Sep 25.
Granell M, Urbano-Ispizua A, Aróstegui JI, Fernández-Avilés F, Martínez C, Rovira M, Rius J, Plaza S, Gaya A, Navarro A, Talarn C, Carreras E, Monzó M, Montserrat E, Yagüe J. Effect of NOD2/CARD15 variants in T-cell depleted allogeneic stem cell transplantation. Haematologica. 2006 Oct;91(10):1372-6.
Giné E, Montoto S, Bosch F, Arenillas L, Mercadal S, Villamor N, Martínez A, Colomo L, Campo E, Montserrat E, López-Guillermo A. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol. 2006 Oct;17(10):1539-45. Epub 2006 Aug 28.
Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, Roncador G, Montserrat E, Campo E, Banham AH. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood. 2006 Nov 1;108(9):2957-64. Epub 2006 Jul 6.

2007

Montserrat E. Response criteria, prognosis, and follow-up in chronic lymphocytic leukemia. In: Sekeres MA, Kalaycio ME, Bolwell BJ, eds. Clinical Malignant Hematology. New York, NY: McGraw Hill; 2007:239-244.
Montserrat E, Emmanouilides C. Changing the paradigm: new perspectives in the treatment of haematological malignancies. Introduction. Haematol Meet Rep. 2007;1(5):1-2
Stamatopoulos K, Belessi C, Moreno C, Boudjograh M, Guida G, Smilevska T, Belhoul L, Stella S, Stavroyianni N, Crespo M, Hadzidimitriou A, Sutton L, Bosch F, Laoutaris N, Anagnostopoulos A, Montserrat E, Fassas A, Dighiero G, Caligaris-Cappio F, Merle-Béral H, Ghia P, Davi F. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood. 2007 Jan 1;109(1):259-70. Epub 2006 Sep 19.
Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J, Wiktor-Jedrzejczak W, Niederwieser D, Hallek M, Montserrat E. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007 Jan;21(1):12-7. Epub 2006 Nov 16.
Salaverria I, Zettl A, Beà S, Moreno V, Valls J, Hartmann E, Ott G, Wright G, Lopez-Guillermo A, Chan WC, Weisenburger DD, Gascoyne RD, Grogan TM, Delabie J, Jaffe ES, Montserrat E, Muller-Hermelink HK, Staudt LM, Rosenwald A, Campo E. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol. 2007 Apr 1;25(10):1216-22. Epub 2007 Feb 12.
Muntañola A, Bosch F, Arguis P, Arellano-Rodrigo E, Ayuso C, Giné E, Crespo M, Abrisqueta P, Moreno C, Cobo F, López-Guillermo A, Montserrat E. Abdominal computed tomography predicts progression in patients with Rai stage 0 chronic lymphocytic leukemia. J Clin Oncol. 2007 Apr 20;25(12):1576-80. Epub 2007 Mar 12.
Rawstron AC, Villamor N, Ritgen M, Böttcher S, Ghia P, Zehnder JL, Lozanski G, Colomer D, Moreno C, Geuna M, Evans PA, Natkunam Y, Coutre SE, Avery ED, Rassenti LZ, Kipps TJ, Caligaris-Cappio F, Kneba M, Byrd JC, Hallek MJ, Montserrat E, Hillmen P. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007 May;21(5):956-64. Epub 2007 Mar 15.
Wiestner A, Tehrani M, Chiorazzi M, Wright G, Gibellini F, Nakayama K, Liu H, Rosenwald A, Muller-Hermelink HK, Ott G, Chan WC, Greiner TC, Weisenburger DD, Vose J, Armitage JO, Gascoyne RD, Connors JM, Campo E, Montserrat E, Bosch F, Smeland EB, Kvaloy S, Holte H, Delabie J, Fisher RI, Grogan TM, Miller TP, Wilson WH, Jaffe ES, Staudt LM. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood. 2007 Jun 1;109(11):4599-606. Epub 2007 Feb 13.
Ferrer A, Salaverria I, Bosch F, Villamor N, Rozman M, Beà S, Giné E, López-Guillermo A, Campo E, Montserrat E. Leukemic involvement is a common feature in mantle cell lymphoma. Cancer. 2007 Jun 15;109(12):2473-80.
Giné E, Moreno C, Esteve J, Montserrat E. The role of stem-cell transplantation in chronic lymphocytic leukemia risk-adapted therapy. Best Pract Res Clin Haematol. 2007 Sep;20(3):529-43.
Martínez C1, Salamero O, Arenillas L, Duque J, López-Guillermo A, Rovira M, Urbano-Ispízua A, Fernández-Avilés F, Carreras E, Montserrat E. Autologous stem cell transplantation for patients with active Hodgkin’s lymphoma: long-term outcome of 61 patients from a single institution. Leuk Lymphoma. 2007 Oct;48(10):1968-75.
Abrisqueta P, Rovira M, Cibeira MT, Vallansot R, Gutiérrez G, Bladé J, Carreras E, Montserrat E. Trasplante autólogo de progenitores hematopoyéticos en el síndrome de POEMS: resultados en 4 casos. Med Clin (Barc). 2007 Oct 27;129(15):578-81.
Fuertes S, Setoain X, López-Guillermo A, Montserrat E, Fuster D, Paredes P, Lomeña F, Pons F. Utilidad de la tomografía por emission de positrons/tomografía computarizada (PET/TC) en el estudio de extension en pacientes con linfoma B difuso de células grandes. Med Clin (Barc). 2007 Nov 17;129(18):688-93.
Talarn C, Urbano-Ispizua A, Martino R, Pérez-Simón JA, Batlle M, Herrera C, Granell M, Gaya A, Torrebadell M, Fernández-Avilés F, Aymerich M, Marín P, Sierra J, Montserrat E. Kinetics of recovery of dendritic cell subsets after reduced-intensity conditioning allogeneic stem cell transplantation and clinical outcome. Haematologica. 2007 Dec;92(12):1655-63.
Pavletic SZ, Zhou G, Sobocinski K, Marti G, Doney K, DiPersio J, Feremans W, Foroni L, Goodman S, Prentice G, LeMaistre C, Bandini G, Ferrant A, Jacobsen N, Khouri I, Gale RP, Wiestner A, Giralt S, Montserrat E, Chan WC, Bredeson C. Genetically identical twin transplantation for chronic lymphocytic leukemia. Leukemia. 2007 Dec;21(12):2452-5. Epub 2007 Aug 30.

2008

Müller-Hermelink HK, Montserrat E, Catovsky D, Campo E, Harris NL, Stein H. Chronic lymphocytic leukaemia/small lymphocytic lymphoma. In Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, Eds. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2008: 216-220.
Campo E, Catovsky D, Montserrat E, Müller-Hermelink HK, Harris NL, Stein H. B-cell prolymphocytic leukaemia. In Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, Eds. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2008: 222-223.
Ferrer A, Bosch F, Villamor N, Rozman M, Graus F, Gutiérrez G, Mercadal S, Campo E, Rozman C, López-Guillermo A, Montserrat E. Central nervous system involvement in mantle cell lymphoma. Ann Oncol. 2008 Jan;19(1):135-41. Epub 2007 Oct 24.
Giné E, Crespo M, Muntañola A, Calpe E, Baptista MJ, Villamor N, Montserrat E, Bosch F. Induction of histone H1.2 cytosolic release in chronic lymphocytic leukemia cells after genotoxic and non-genotoxic treatment. Haematologica. 2008 Jan;93(1):75-82.
Fernàndez V, Jares P, Salaverria I, Giné E, Beà S, Aymerich M, Colomer D, Villamor N, Bosch F, Montserrat E, Campo E. Gene expression profile and genomic changes in disease progression of early-stage chronic lymphocytic leukemia. Haematologica. 2008 Jan;93(1):132-6.
Bosch F, Ferrer A, Villamor N, González M, Briones J, González-Barca E, Abella E, Gardella S, Escoda L, Pérez-Ceballos E, Asensi A, Sayas MJ, Font L, Altés A, Muntañola A, Bertazzoni P, Rozman M, Aymerich M, Giné E, Montserrat E. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res. 2008 Jan 1;14(1):155-61.
Montoto S, Moreno C, Domingo-Doménech E, Estany C, Oriol A, Altés A, Besalduch J, Pedro C, Gardella S, Escoda L, Asensio A, Vivancos P, Galán P, de Sevilla AF, Ribera JM, Briones J, Colomer D, Campo E, Montserrat E, López-Guillermo A. High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. Haematologica. 2008 Feb;93(2):207-14. Epub 2008 Jan 26.
Navarro A, Gaya A, Martinez A, Urbano-Ispizua A, Pons A, Balagué O, Gel B, Abrisqueta P, Lopez-Guillermo A, Artells R, Montserrat E, Monzo M. MicroRNA expression profiling in classic Hodgkin lymphoma. Blood. 2008 Mar 1;111(5):2825-32. Epub 2007 Dec 18.
Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C, Camós M, Colomo L, Espinosa I, Martínez S, Ribera JM, Martino R, Gutiérrez-García G, Montserrat E, López-Guillermo A. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol. 2008 May;19(5):958-63. Epub 2008 Feb 25.
Fouillard L, Labopin M, Gratwohl A, Gluckman E, Frassoni F, Beelen DW, Willemze R, Montserrat E, Blaise D, Atienza AI, Sierra J, Santos M, Gorin NC, Rocha V; Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission. Haematologica. 2008 Jun;93(6):834-41. Epub 2008 May 10.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008 Jun 15;111(12):5446-56. Epub 2008 Jan 23.
Moreno C, Montserrat E. New prognostic markers in chronic lymphocytic leukemia. Blood Rev. 2008 Jul;22(4):211-9. Epub 2008 Apr 29.
Gaya A, Urbano-Ispizua A, Fernández-Avilés F, Salamero O, Roncero JM, Rovira M, Martínez C, Talarn C, Granell M, Carreras E, Montserrat E. Anemia associated with impaired erythropoietin secretion after allogeneic stem cell transplantation: incidence, risk factors, and response to treatment. Biol Blood Marrow Transplant. 2008 Aug;14(8):880-7.
Montserrat E. Further progress in CLL therapy. Blood. 2008 Aug 15;112(4):924-5.
Montserrat E, Moreno C. Chronic lymphocytic leukaemia: a short overview. Ann Oncol. 2008 Sep;19(Suppl 7):vii320-5.
Pérez-Galán P, Roué G, López-Guerra M, Nguyen M, Villamor N, Montserrat E, Shore GC, Campo E, Colomer D. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia. 2008 Sep;22(9):1712-20. Epub 2008 Jul 3.
Granell M, Urbano-Ispizua A, Pons A, Aróstegui JI, Gel B, Navarro A, Jansa S, Artells R, Gaya A, Talarn C, Fernández-Avilés F, Martínez C, Rovira M, Carreras E, Rozman C, Juan M, Yagüe J, Montserrat E, Monzó M. Common variants in NLRP2 and NLRP3 genes are strong prognostic factors for the outcome of HLA-identical sibling allogeneic stem cell transplantation. Blood. 2008 Nov 15;112(10):4337-42. Epub 2008 Sep 4.
Roué G, López-Guerra M, Milpied P, Pérez-Galán P, Villamor N, Montserrat E, Campo E, Colomer D. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clin Cancer Res. 2008 Nov 1;14(21):6907-15.
Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008 Nov 27;359(22):2313-23.
López-Guerra M, Trigueros-Motos L, Molina-Arcas M, Villamor N, Casado FJ, Montserrat E, Campo E, Colomer D, Pastor-Anglada M. Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells. Haematologica. 2008 Dec;93(12):1843-51. Epub 2008 Oct 22.
Enjuanes A, Benavente Y, Bosch F, Martín-Guerrero I, Colomer D, Pérez-Alvarez S, Reina O, Ardanaz MT, Jares P, García-Orad A, Pujana MA, Montserrat E, de Sanjosé S, Campo E. Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. Cancer Res. 2008 Dec 15;68(24):10178-86.

2009

Carreras J, Lopez-Guillermo A, Roncador G, Villamor N, Colomo L, Martinez A, Hamoudi R, Howat WJ, Montserrat E, Campo E. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol. 2009 Mar 20;27(9):1470-6. Epub 2009 Feb 17.
Suzumiya J, Ohshima K, Tamura K, Karube K, Uike N, Tobinai K, Gascoyne RD, Vose JM, Armitage JO, Weisenburger DD; International Peripheral T-Cell Lymphoma Project. The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project. Ann Oncol. 2009 Apr;20(4):715-21. Epub 2009 Jan 15.
López-Guerra M, Roué G, Pérez-Galán P, Alonso R, Villamor N, Montserrat E, Campo E, Colomer D. p65 activity and ZAP-70 status predict the sensitivity of chronic lymphocytic leukemia cells to the selective IkappaB kinase inhibitor BMS-345541. Clin Cancer Res. 2009 Apr 15;15(8):2767-76. Epub 2009 Apr 7.
Codony C, Crespo M, Abrisqueta P, Montserrat E, Bosch F. Gene expression profiling in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol. 2009 Jun;22(2):211-22.
Ferrer G, Hodgson K, Montserrat E, Moreno C. B cell activator factor and a proliferation-inducing ligand at the cross-road of chronic lymphocytic leukemia and autoimmunity. Leuk Lymphoma. 2009 Jul;50(7):1075-82.
Montserrat E. Unfolding a CLL mystery. Blood. 2009 Jul 16;114(3):498.
Alonso R, López-Guerra M, Upshaw R, Bantia S, Smal C, Bontemps F, Manz C, Mehrling T, Villamor N, Campo E, Montserrat E, Colomer D. Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM. Blood. 2009 Aug 20;114(8):1563-75. Epub 2009 Jun 18.
Abrisqueta P, Pereira A, Rozman C, Aymerich M, Giné E, Moreno C, Muntañola A, Rozman M, Villamor N, Hodgson K, Campo E, Bosch F, Montserrat E. Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. Blood. 2009 Sep 3;114(10):2044-50. Epub 2009 Jun 24.
Bosch F, Abrisqueta P, Villamor N, Terol MJ, González-Barca E, Ferra C, González Diaz M, Abella E, Delgado J, Carbonell F, García Marco JA, Escoda L, Ferrer S, Monzó E, González Y, Estany C, Jarque I, Salamero O, Muntañola A, Montserrat E. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol. 2009 Sep 20;27(27):4578-84. Epub 2009 Aug 24.
Navarro A, Diaz T, Martinez A, Gaya A, Pons A, Gel B, Codony C, Ferrer G, Martinez C, Montserrat E, Monzo M. Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood. 2009 Oct 1;114(14):2945-51. Epub 2009 Aug 7.
Montserrat E, Moreno C. Genetic lesions in chronic lymphocytic leukemia: clinical implications. Curr Opin Oncol. 2009 Nov;21(6):609-14.
Pons A, Nomdedeu B, Navarro A, Gaya A, Gel B, Diaz T, Valera S, Rozman M, Belkaid M, Montserrat E, Monzo M. Hematopoiesis-related microRNA expression in myelodysplastic syndromes. Leuk Lymphoma. 2009 Nov;50(11):1854-9.

2010

Catovsky D, Montserrat E. Chronic lymphocytic leukaemia and other B-cell disorders. In Hoffbrand AV, Catovsky D, Tuddenham EGD, Green AR, Eds. Postgraduate Haematology. Sixth edition. Oxford, UK: Wiley-Blackwell; 2010: 530-557.
Montserrat E. Advances in biology and therapy of chronic lymphocytic leukemia. Preface. Best Pract Res Clin Haematol. 2010 Mar;23(1):1-2.
Moreno C, Montserrat E. Genetic lesions in chronic lymphocytic leukemia: what’s ready for prime time use? Haematologica. 2010 Jan;95(1):12-5.
Crowther-Swanepoel D, Broderick P, Di Bernardo MC, Dobbins SE, Torres M, Mansouri M, Ruiz-Ponte C, Enjuanes A, Rosenquist R, Carracedo A, Jurlander J, Campo E, Juliusson G, Montserrat E, Smedby KE, Dyer MJ, Matutes E, Dearden C, Sunter NJ, Hall AG, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Parker A, Oscier D, Allan JM, Catovsky D, Houlston RS. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet. 2010 Feb;42(2):132-6. Epub 2010 Jan 10.
Fernàndez V, Salamero O, Espinet B, Solé F, Royo C, Navarro A, Camacho F, Beà S, Hartmann E, Amador V, Hernández L, Agostinelli C, Sargent RL, Rozman M, Aymerich M, Colomer D, Villamor N, Swerdlow SH, Pileri SA, Bosch F, Piris MA, Montserrat E, Ott G, Rosenwald A, López-Guillermo A, Jares P, Serrano S, Campo E. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010 Feb 15;70(4):1408-18. Epub 2010 Feb 2.
Montserrat E. Advances in biology and therapy of chronic lymphocytic leukemia. Preface. Best Pract Res Clin Haematol. 2010 Mar;23(1):1-2.
International Cancer Genome Consortium, Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabé RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, Guttmacher A, Guyer M, Hemsley FM, Jennings JL, Kerr D, Klatt P, Kolar P, Kusada J, Lane DP, Laplace F, Youyong L, Nettekoven G, Ozenberger B, Peterson J, Rao TS, Remacle J, Schafer AJ, Shibata T, Stratton MR, Vockley JG, Watanabe K, Yang H, Yuen MM, Knoppers BM, Bobrow M, Cambon-Thomsen A, Dressler LG, Dyke SO, Joly Y, Kato K, Kennedy KL, Nicolás P, Parker MJ, Rial-Sebbag E, Romeo-Casabona CM, Shaw KM, Wallace S, Wiesner GL, Zeps N, Lichter P, Biankin AV, Chabannon C, Chin L, Clément B, de Alava E, Degos F, Ferguson ML, Geary P, Hayes DN, Hudson TJ, Johns AL, Kasprzyk A, Nakagawa H, Penny R, Piris MA, Sarin R, Scarpa A, Shibata T, van de Vijver M, Futreal PA, Aburatani H, Bayés M, Botwell DD, Campbell PJ, Estivill X, Gerhard DS, Grimmond SM, Gut I, Hirst M, López-Otín C, Majumder P, Marra M, McPherson JD, Nakagawa H, Ning Z, Puente XS, Ruan Y, Shibata T, Stratton MR, Stunnenberg HG, Swerdlow H, Velculescu VE, Wilson RK, Xue HH, Yang L, Spellman PT, Bader GD, Boutros PC, Campbell PJ, Flicek P, Getz G, Guigó R, Guo G, Haussler D, Heath S, Hubbard TJ, Jiang T, Jones SM, Li Q, López-Bigas N, Luo R, Muthuswamy L, Ouellette BF, Pearson JV, Puente XS, Quesada V, Raphael BJ, Sander C, Shibata T, Speed TP, Stein LD, Stuart JM, Teague JW, Totoki Y, Tsunoda T, Valencia A, Wheeler DA, Wu H, Zhao S, Zhou G, Stein LD, Guigó R, Hubbard TJ, Joly Y, Jones SM, Kasprzyk A, Lathrop M, López-Bigas N, Ouellette BF, Spellman PT, Teague JW, Thomas G, Valencia A, Yoshida T, Kennedy KL, Axton M, Dyke SO, Futreal PA, Gerhard DS, Gunter C, Guyer M, Hudson TJ, McPherson JD, Miller LJ, Ozenberger B, Shaw KM, Kasprzyk A, Stein LD, Zhang J, Haider SA, Wang J, Yung CK, Cros A, Liang Y, Gnaneshan S, Guberman J, Hsu J, Bobrow M, Chalmers DR, Hasel KW, Joly Y, Kaan TS, Kennedy KL, Knoppers BM, Lowrance WW, Masui T, Nicolás P, Rial-Sebbag E, Rodriguez LL, Vergely C, Yoshida T, Grimmond SM, Biankin AV, Bowtell DD, Cloonan N, deFazio A, Eshleman JR, Etemadmoghadam D, Gardiner BB, Kench JG, Scarpa A, Sutherland RL, Tempero MA, Waddell NJ, Wilson PJ, McPherson JD, Gallinger S, Tsao MS, Shaw PA, Petersen GM, Mukhopadhyay D, Chin L, DePinho RA, Thayer S, Muthuswamy L, Shazand K, Beck T, Sam M, Timms L, Ballin V, Lu Y, Ji J, Zhang X, Chen F, Hu X, Zhou G, Yang Q, Tian G, Zhang L, Xing X, Li X, Zhu Z, Yu Y, Yu J, Yang H, Lathrop M, Tost J, Brennan P, Holcatova I, Zaridze D, Brazma A, Egevard L, Prokhortchouk E, Banks RE, Uhlén M, Cambon-Thomsen A, Viksna J, Ponten F, Skryabin K, Stratton MR, Futreal PA, Birney E, Borg A, Børresen-Dale AL, Caldas C, Foekens JA, Martin S, Reis-Filho JS, Richardson AL, Sotiriou C, Stunnenberg HG, Thoms G, van de Vijver M, van’t Veer L, Calvo F, Birnbaum D, Blanche H, Boucher P, Boyault S, Chabannon C, Gut I, Masson-Jacquemier JD, Lathrop M, Pauporté I, Pivot X, Vincent-Salomon A, Tabone E, Theillet C, Thomas G, Tost J, Treilleux I, Calvo F, Bioulac-Sage P, Clément B, Decaens T, Degos F, Franco D, Gut I, Gut M, Heath S, Lathrop M, Samuel D, Thomas G, Zucman-Rossi J, Lichter P, Eils R, Brors B, Korbel JO, Korshunov A, Landgraf P, Lehrach H, Pfister S, Radlwimmer B, Reifenberger G, Taylor MD, von Kalle C, Majumder PP, Sarin R, Rao TS, Bhan MK, Scarpa A, Pederzoli P, Lawlor RA, Delledonne M, Bardelli A, Biankin AV, Grimmond SM, Gress T, Klimstra D, Zamboni G, Shibata T, Nakamura Y, Nakagawa H, Kusada J, Tsunoda T, Miyano S, Aburatani H, Kato K, Fujimoto A, Yoshida T, Campo E, López-Otín C, Estivill X, Guigó R, de Sanjosé S, Piris MA, Montserrat E, González-Díaz M, Puente XS, Jares P, Valencia A, Himmelbauer H, Quesada V, Bea S, Stratton MR, Futreal PA, Campbell PJ, Vincent-Salomon A, Richardson AL, Reis-Filho JS, van de Vijver M, Thomas G, Masson-Jacquemier JD, Aparicio S, Borg A, Børresen-Dale AL, Caldas C, Foekens JA, Stunnenberg HG, van’t Veer L, Easton DF, Spellman PT, Martin S, Barker AD, Chin L, Collins FS, Compton CC, Ferguson ML, Gerhard DS, Getz G, Gunter C, Guttmacher A, Guyer M, Hayes DN, Lander ES, Ozenberger B, Penny R, Peterson J, Sander C, Shaw KM, Speed TP, Spellman PT, Vockley JG, Wheeler DA, Wilson RK, Hudson TJ, Chin L, Knoppers BM, Lander ES, Lichter P, Stein LD, Stratton MR, Anderson W, Barker AD, Bell C, Bobrow M, Burke W, Collins FS, Compton CC, DePinho RA, Easton DF, Futreal PA, Gerhard DS, Green AR, Guyer M, Hamilton SR, Hubbard TJ, Kallioniemi OP, Kennedy KL, Ley TJ, Liu ET, Lu Y, Majumder P, Marra M, Ozenberger B, Peterson J, Schafer AJ, Spellman PT, Stunnenberg HG, Wainwright BJ, Wilson RK, Yang H. International network of cancer genome projects. Nature. 2010 Apr 15;464(7291):993-8.
Fernández de Larrea C, Martínez C, Gaya A, López-Guillermo A, Rovira M, Fernández-Avilés F, Lozano M, Bosch F, Esteve J, Nomdedeu B, Montserrat E, Carreras E. Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin’s lymphoma followed by autologous stem-cell transplantation. Ann Oncol. 2010 Jun;21(6):1211-6. Epub 2009 Nov 4.
Gutiérrez-García G, Colomo L, Villamor N, Arenillas L, Martínez A, Cardesa T, García-Herrera A, Setoain X, Rodríguez S, Ghita G, Abrisqueta P, Giné E, Bosch F, Campo E, Montserrat E, López-Guillermo A. Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma. 2010 Jul;51(7):1225-32.
Crowther-Swanepoel D, Mansouri M, Enjuanes A, Vega A, Smedby KE, Ruiz-Ponte C, Jurlander J, Juliusson G, Montserrat E, Catovsky D, Campo E, Carracedo A, Rosenquist R, Houlston RS. Verification that common variation at 2q37.1, 6p25.3, 11q24.1, 15q23, and 19q13.32 influences chronic lymphocytic leukaemia risk. Br J Haematol. 2010 Aug;150(4):473-9. Epub 2010 Jun 10.
Giné E, Martinez A, Villamor N, López-Guillermo A, Camos M, Martinez D, Esteve J, Calvo X, Muntañola A, Abrisqueta P, Rozman M, Rozman C, Bosch F, Campo E, Montserrat E. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica. 2010 Sep;95(9):1526-33. Epub 2010 Apr 26.
Wierda WG, Chiorazzi N, Dearden C, Brown JR, Montserrat E, Shpall E, Stilgenbauer S, Muneer S, Grever M. Chronic lymphocytic leukemia: new concepts for future therapy. Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):369-78.
Moreno C, Hodgson K, Ferrer G, Elena M, Filella X, Pereira A, Baumann T, Montserrat E. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood. 2010 Dec 2;116(23):4771-6. Epub 2010 Aug 24.

2011

Hodgson K, Ferrer G, Montserrat E, Moreno C. Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica. 2011 May;96(5):752-61. Epub 2011 Jan 17.
Fernández de Larrea C, Martínez-Pozo A, Mercadal S, García A, Gutierrez-García G, Valera A, Ghita G, Colomo L, Gainza E, Villamor N, Nomdedeu B, Estrach T, Montserrat E, Campo E, López-Guillermo A. Initial features and outcome of cutaneous and non-cutaneous primary extranodal follicular lymphoma. Br J Haematol. 2011 May;153(3):334-40. Epub 2011 Mar 6.
Puente XS, Pinyol M, Quesada V, Conde L, Ordóñez GR, Villamor N, Escaramis G, Jares P, Beà S, González-Díaz M, Bassaganyas L, Baumann T, Juan M, López-Guerra M, Colomer D, Tubío JM, López C, Navarro A, Tornador C, Aymerich M, Rozman M, Hernández JM, Puente DA, Freije JM, Velasco G, Gutiérrez-Fernández A, Costa D, Carrió A, Guijarro S, Enjuanes A, Hernández L, Yagüe J, Nicolás P, Romeo-Casabona CM, Himmelbauer H, Castillo E, Dohm JC, de Sanjosé S, Piris MA, de Alava E, San Miguel J, Royo R, Gelpí JL, Torrents D, Orozco M, Pisano DG, Valencia A, Guigó R, Bayés M, Heath S, Gut M, Klatt P, Marshall J, Raine K, Stebbings LA, Futreal PA, Stratton MR, Campbell PJ, Gut I, López-Guillermo A, Estivill X, Montserrat E, López-Otín C, Campo E. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011 Jun 5;475(7354):101-5.
Montserrat E, Gribben JG. Autografting CLL: the game is over! Blood. 2011 Jun 9;117(23):6057-8.
Hodgson K, Ferrer G, Pereira A, Moreno C, Montserrat E. Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment. Br J Haematol. 2011 Jul;154(1):14-22. Epub 2011 May 1.
Delabie J, Holte H, Vose JM, Ullrich F, Jaffe ES, Savage KJ, Connors JM, Rimsza L, Harris NL, Müller-Hermelink K, Rüdiger T, Coiffier B, Gascoyne RD, Berger F, Tobinai K, Au WY, Liang R, Montserrat E, Hochberg EP, Pileri S, Federico M, Nathwani B, Armitage JO, Weisenburger DD. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood. 2011 Jul 7;118(1):148-55. Epub 2011 May 12.
Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011 Sep;22(Suppl 6):vi50-4.
Ferrer G, Hodgson K, Pereira A, Juan M, Elena M, Colomer D, Roué G, Aymerich M, Baumann T, Montserrat E, Moreno C. Combined analysis of levels of serum B-cell activating factor and a proliferation-inducing ligand as predictor of disease progression in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2011 Nov;52(11):2064-8. Epub 2011 Jun 27.

2012

Delgado J, Baumann T, Ghita G, Montserrat E. Chronic lymphocytic leukemia therapy: beyond chemoimmunotherapy. Curr Pharm Des. 2012;18(23):3356-62.
Montserrat E. PTLD treatment: a step forward, a long way to go. Lancet Oncol. 2012 Feb;13(2):120-1. Epub 2011 Dec 13.
López C, Baumann T, Costa D, López-Guerra M, Navarro A, Gómez C, Arias A, Muñoz C, Rozman M, Villamor N, Colomer D, Montserrat E, Campo E, Carrió A. A new genetic abnormality leading to TP53 gene deletion in chronic lymphocytic leukaemia. Br J Haematol. 2012 Mar;156(5):612-8. Epub 2011 Dec 9.
Ferrer G, Moreno C, Montserrat E. Comment on “Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors”. J Immunol. 2012 Apr 1;188(7):2930-1; author reply 2931.
López-Guerra M, Xargay-Torrent S, Pérez-Galán P, Saborit-Villarroya I, Rosich L, Villamor N, Aymerich M, Roué G, Campo E, Montserrat E, Colomer D. Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells. Leukemia. 2012 Jun;26(6):1429-32. Epub 2011 Dec 20.
Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP, Cymbalista F, Eichhorst B, Hallek M, Döhner H, Hillmen P, van Oers M, Gribben J, Ghia P, Montserrat E, Stilgenbauer S, Zenz T. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia. 2012 Jul;26(7):1458-61. Epub 2012 Feb 2.
Nicolosi Guidicelli S, Lopez-Guillermo A, Falcone U, Conconi A, Christinat A, Rodriguez-Abreu D, Grisanti S, Lobetti-Bodoni C, Piffaretti JC, Johnson PW, Mombelli G, Cerny A, Montserrat E, Cavalli F, Zucca E. Hepatitis C virus and GBV-C virus prevalence among patients with B-cell lymphoma in different European regions: a case-control study of the International Extranodal Lymphoma Study Group. Hematol Oncol. 2012 Sep;30(3):137-42. Epub 2011 Nov 21.
López C, Delgado J, Costa D, Conde L, Ghita G, Villamor N, Navarro A, Cazorla M, Gómez C, Arias A, Muñoz C, Baumann T, Rozman M, Aymerich M, Colomer D, Cobo F, Campo E, López-Guillermo A, Montserrat E, Carrió A. Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations. Genes Chromosomes Cancer. 2012 Sep;51(9):881-9. Epub 2012 May 23.
Montserrat E. CLL therapy: the increasing importance of predictive markers. Oncology (Williston Park). 2012 Nov;26(11):1064-6.

2013

Montserrat E. Small Lymphocytic Leukemia/Chronic Lymphocytic Leukemia. In: Younes A, Coiffier B, eds. Lymphoma, Current Clinical Oncology, Vol. 43. New York: Humana Press; 2013: 65-82.
Rawstron AC, Böttcher S, Letestu R, Villamor N, Fazi C, Kartsios H, de Tute RM, Shingles J, Ritgen M, Moreno C, Lin K, Pettitt AR, Kneba M, Montserrat E, Cymbalista F, Hallek M, Hillmen P, Ghia P. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia. 2013 Jan;27(1):142-9. Epub 2012 Jul 31.
Burger JA, Montserrat E. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood. 2013 Feb 28;121(9):1501-9. Epub 2012 Dec 20.
Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, Federico M, Hoskin P, McNamara C, Caligaris-Cappio F, Stilgenbauer S, Marcus R, Trneny M, Dreger P, Montserrat E, Dreyling M. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol. 2013 Mar;24(3):561-76. Epub 2012 Nov 21.
Ferrer G, Navarro A, Hodgson K, Aymerich M, Pereira A, Baumann T, Monzo M, Moreno C, Montserrat E. MicroRNA expression in chronic lymphocytic leukemia developing autoimmune hemolytic anemia. Leuk Lymphoma. 2013 Sep;54(9):2016-22. Epub 2013 Jan 29.
Baumann T, Delgado J, Santacruz R, Martínez-Trillos A, Royo C, Navarro A, Pinyol M, Rozman M, López C, Villamor N, Aymerich M, Pereira A, Carrió, A, Montserrat E. Initial characteristics, treatment and prognosis of elderly (≥ 70 years) patients with chronic lymphocytic leukemia (CLL): an analysis of a series of 367 cases. Blood. 2013 Nov;122(21):4155-4155.
Abrisqueta P, Villamor N, Terol MJ, González-Barca E, González M, Ferrà C, Abella E, Delgado J, García-Marco JA, González Y, Carbonell F, Ferrer S, Monzó E, Jarque I, Muntañola A, Constants M, Escoda L, Calvo X, Bobillo S, Montoro JB, Montserrat E, Bosch F. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood. 2013 Dec 5;122(24):3951-9. Epub 2013 Oct 11.

2014

Ferrer G, Bosch R, Hodgson K, Tejero R, Roué G, Colomer D, Montserrat E, Moreno C. B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL. Br J Haematol. 2014 Feb;164(4):570-8. Epub 2013 Nov 18.
Delgado J, Ghita G, Baumann T, Santacruz R, Dlouhy I, Aymerich M, Rozman M, Creus N, Pereira A, Montserrat E. Rituximab-based chemoimmunotherapy prolongs survival of patients with chronic lymphocytic leukemia independently of the time of administration. Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):73-9. Epub 2013 Oct 12.
Delgado J, Baumann T, Santacruz R, Montserrat E. New treatment options for chronic lymphocytic leukemia. Expert Opin Pharmacother. 2014 Apr;15(6):823-32. Epub 2014 Feb 22.
Montserrat E. Prognostic factors in chronic lymphocytic leukemia: a conceptual approach. Int J Hematol Oncol. 2014 Apr;3(2):145-52.
Moreno-Martínez D, Nomdedeu M, Lara-Castillo MC, Etxabe A, Pratcorona M, Tesi N, Díaz-Beyá M, Rozman M, Montserrat E, Urbano-Ispizua A, Esteve J, Risueño RM. XIAP inhibitors induce differentiation and impair clonogenic capacity of acute myeloid leukemia stem cells. Oncotarget. 2014 Jun 30;5(12):4337-46.
Benner A, Mansouri L, Rossi D, Majid A, Willander K, Parker A, Bond G, Pavlova S, Nückel H, Merkel O, Ghia P, Montserrat E, Kaderi MA, Rosenquist R, Gaidano G, Dyer MJ, Söderkvist P, Linderholm 5, Oscier D, Tvaruzkova Z, Pospisilova S, Dührsen U, Greil R, Döhner H, Stilgenbauer S, Zenz T. MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis. Haematologica. 2014 Aug;99(8):1285-91.
Baumann T, Delgado J, Santacruz R, Martínez-Trillos A, Royo C, Navarro A, Pinyol M, Rozman M, Pereira A, Villamor N, Aymerich M, López C, Carrió A, Montserrat E. Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model. Haematologica. 2014 Oct;99(10):1599-604. Epub 2014 Jun 27.
Rawstron A, Fazi C, Villamor N, Delgado J, Letestu R, Cymbalista F, Palacio C, Bosch F, De Tute RM, Liptrot S, O’Brien D, Spacek M, Dobber J, Kater AP, Gambell PC, Westerman DA, Soosapilla A, Mulligan SP, Lozanski G, Lin K, Pettitt AR, Brachtl G, Egle A, Williamson DW, Sanders CM, Robins H, Boysen J, Shanafelt TD, Hanson CA, Jorgensen JL, Wierda WG, Yuan C, Stetler-Stevenson M, Rassenti L, Broome HE, Kipps TJ, Hauwel M, Marinov I, Craig FE, Josep N, Moreno C, Stehlikova O, Doubek M, Pospisilova S, Kreuzer KA, Hallek M, Hillmen P, Montserrat E, Ghia P. A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study. Blood. 2014 Dec 6;124(21):1976-1976.
Dreger P, Schetelig J, Andersen N, Corradini P, van Gelder M, Gribben J, Kimby E, Michallet M, Moreno C, Stilgenbauer S, Montserrat E. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood. 2014 Dec 18;124(26):3841-9. Epub 2014 Oct 9.

2015

Dreger P, Montserrat E. Where does allogeneic stem cell transplantation fit in the treatment of chronic lymphocytic leukemia? Curr Hematol Malig Rep. 2015 Mar;10(1):59-64. https://doi.org/10.1007/s11899-014-0242-1
Moreno C, Montillo M, Panayiotidis P, Dimou M, Bloor A, Dupuis J, Schuh A, Norin S, Geisler C, Hillmen P, Doubek M, Trněný M, Obrtlikova P, Laurenti L, Stilgenbauer S, Smolej L, Ghia P, Cymbalista F, Jaeger U, Stamatopoulos K, Stavroyianni N, Carrington P, Zouabi H, Leblond V, Gomez-Garcia JC, Rubio M, Marasca R, Musuraca G, Rigacci L, Farina L, Paolini R, Pospisilova S, Kimby E, Bradley C, Montserrat E. Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. Haematologica. 2015 Apr;100(4):511-6. Epub 2015 Jan 16.
Montserrat E, Dreger P. Hope for high-risk chronic lymphocytic leukemia relapsing after allogeneic stem-cell transplantation. J Clin Oncol. 2015 May 10;33(14):1527-9. Epub 2015 Apr 13.
Montserrat E. Primary CNS lymphoma: in search of the evidence. Lancet Haematol. 2015 Jun;2(6):e227-8. Epub 2015 Jun 3.
Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26(Suppl 5):v78-84.
Conconi A, Lobetti-Bodoni C, Montoto S, Lopez-Guillermo A, Coutinho R, Matthews J, Franceschetti S, Bertoni F, Moccia A, Rancoita PM, Gribben J, Cavalli F, Gaidano G, Lister TA, Montserrat E, Ghielmini M, Zucca E. Life expectancy of young adults with follicular lymphoma. Ann Oncol. 2015 Nov;26(11):2317-22. Epub 2015 Sep 11.

2016

Montserrat E, Hillmen P. Chronic Lymphocytic Leukemia and other B-cell chronic lymphoproliferative disorders. In: Hoffbrand AV, Higgs DR, Keeling D, Mehta AB, eds. Postgraduate Haematology. Chichester, UK; Hoboken, NJ: Wiley Blackwell; 2016: 500-523.
Dreger P, Montserrat E. Transplantation in CLL: what we can learn from a dinosaur. Bone Marrow Transplant. 2016 Jun;51(6):765-6. Epub 2016 Feb 29.
Baumann T, Delgado J, Santacruz R, Martínez-Trillos A, Rozman M, Aymerich M, López C, Costa D, Carrió A, Villamor N, Montserrat E. CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status. Br J Haematol. 2016 Jan;172(1):48-55. Epub 2015 Nov 12.
Montserrat E, Dreger P. Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors? Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S74-81.
Delgado J, Montserrat E. Maintenance therapy in chronic lymphocytic leukaemia. Lancet Haematol. 2016 Sep;3(9):e399-400. Epub 2016 Aug 1.
Montserrat E, Bauman T, Delgado J. Present and future of personalized medicine in CLL. Best Pract Res Clin Haematol. 2016 Mar;29(1):100-110. Epub 2016 Aug 12.
Pospisilova S, Sutton LA, Malcikova J, Tausch E, Rossi D, Montserrat E, Moreno C, Stamatopoulos K, Gaidano G, Rosenquist R, Ghia P; European Research Initiative on CLL (ERIC). Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go? Haematologica. 2016 Mar;101(3):263-5.
Conconi A, Montoto S, Montserrat E, Zucca E. Reply to the letter to the editor ‘Survival in young adults diagnosed with follicular lymphoma’ by Calvo et al. Ann Oncol. 2016 Jun;27(6):1173. Epub 2016 Feb 18.
Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, Palacio C, Stehlikova O, Kreuzer KA, Liptrot S, O’Brien D, de Tute RM, Marinov I, Hauwel M, Spacek M, Dobber J, Kater AP, Gambell P, Soosapilla A, Lozanski G, Brachtl G, Lin K, Boysen J, Hanson C, Jorgensen JL, Stetler-Stevenson M, Yuan C, Broome HE, Rassenti L, Craig F, Delgado J, Moreno C, Bosch F, Egle A, Doubek M, Pospisilova S, Mulligan S, Westerman D, Sanders CM, Emerson R, Robins HS, Kirsch I, Shanafelt T, Pettitt A, Kipps TJ, Wierda WG, Cymbalista F, Hallek M, Hillmen P, Montserrat E, Ghia P. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia. 2016 Apr;30(4):929-36. Epub 2015 Dec 7.
Montserrat E, Delgado J. CLL: ibrutinib and transplantation ride together. Bone Marrow Transplant. 2016 Jun;51(6):769-70. Epub 2016 May 9.
Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C. appendix 6: Chronic lymphocytic leukaemia: eUpdate published online September 2016. Ann Oncol. 2016 Sep;27(suppl 5):v143-v144.
Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro JE, Furman RR, Gribben J, Hill BT, Mohty M, Moreno C, O’Brien S, Pavletic SZ, Pinilla-Ibarz J, Reddy NM, Sorror M, Bredeson C, Carpenter P, Savani BN. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2016 Dec;22(12):2117-2125. Epub 2016 Sep 19.

2017

Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017 Feb 2;129(5):553-560. Epub 2016 Nov 30.
Molica S, Montserrat E. CLL: when the target of treatment is disease-related symptoms. Lancet Haematol. 2017 Feb;4(2):e57-e58. Epub 2017 Jan 12.
Delgado J, Doubek M, Baumann T, Kotaskova J, Molica S, Mozas P, Rivas-Delgado A, Morabito F, Pospisilova S, Montserrat E. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. Am J Hematol. 2017 Apr;92(4):375-380. Epub 2017 Feb 13.
Molica S, Giannarelli D, Mirabelli R, Levato L, Gentile M, Morabito F, Montserrat E. Reliability of six prognostic models to predict time-to-first-treatment in patients with chronic lymphocytic leukaemia in early phase. Am J Hematol. 2017 Jun;92(6):E91-E93. Epub 2017 Mar 24.
Montserrat E. Prognostic and Predictive Markers in CLL. Clin Lymphoma Myeloma Leuk. 2017 Sep;17(suppl 2):S197-200.
Bosch R, Mora A, Vicente E, Ferrer G, Jansà S, Damle R, Gorlatov S, Rai K, Montserrat E, Nomdedeu J, Pratcorona M, Blanco L, Saavedra S, Garrido A, Esquirol A, Garcia I, Granell M, Martino R, Delgado J, Sierra J, Chiorazzi N, Moreno C. FcγRIIb expression in early stage chronic lymphocytic leukemia. Leuk Lymphoma. 2017 Nov;58(11):2642-2648. Epub 2017 Apr 4.
Marsilio S, Khiabanian H, Fabbri G, Scuoppo C, Vergani S, Devereux S, Montserrat E, Shpall EJ, Hadigol M, Rai K, Rabadan R. CLL mutations in the earliest cells of the hematopoietic lineage: documentation and need for caution. Leuk Lymphoma. 2017 Dec;58(Suppl 1):135-136.
Baumann T, Doubek M, Kotaskova J, Molica S, Mozas P, Rivas-Delgado A, Morabito F, Pospisilova S, Delgado J, Montserrat E. The Barcelona-Brno Biomarkers-Only (IGHV mutational status and FISH cytogenetics) prognostic model for chronic lymphocytic leukemia. Leuk Lymphoma. 2017 Dec;58(Suppl 1):147-149.

2018

Marsilio S, Khiabanian H, Fabbri G, Vergani S, Scuoppo C, Montserrat E, Shpali EJ, Hadigol M, Marin P, Rai KR, Rabadan R, Devereux S, Pasqualucci L, Chiorazzi N. Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: documentation and cautionary note regarding cell fraction purity. Leukemia. 2018;32: 1041-1044.
Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, McIver-Brown N, Villamor N, Psarra K, Arroz M, Milani R, de la Serna J, Cedena MT, Jaksic O, Nomdedeu J, Moreno C, Rigolin GM, Cuneo A, Johansen P, Johnsen HE, Rosenquist R, Niemann CU, Kern W, Westerman D, Trneny M, Mulligan S, Doubek M, Pospisilova S, Hillmen P, Oscier D, Hallek M, Ghia P, Montserrat E. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry B Clin Cytom. 2018 Jan;94(1):121-128. Epub 2018 Jan 17.
Mozas P, Rivas-Delgado A, Baumann T, Villamor N, Ortiz-Maldonado V, Aymerich M, Costa D, Navarro A, Giné E, López-Guillermo A, Montserrat E, Delgado J. Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia. Blood Cancer J. 2018 Jan 16;8(1):10.
Ferrer G, Montserrat E. Critical molecular pathways in CLL therapy. Mol Med. 2018 Mar 15;24(1):9.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O’Brien S, Robak T, Seymour JF, Kipps TJ. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 Jun 21;131(25):2745-2760. Epub 2018 Mar 14.
Dreger P, Ghia P, Schetelig J, van Gelder M, Kimby E, Michallet M, Moreno C, Robak T, Stilgenbauer S, Montserrat E. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood. 2018 Aug 30;132(9):892-902. Epub 2018 Jul 11.

2019

Molica S, Montserrat E. Novel pathway inhibitors for the treatment of chronic lymphocytic leukaemia. Lancet Haematol. 2019 Feb;6(2):e65-e66.
Moreno C, Delgado J, Byrd JC, Zvagelsky WL, Suzuki S, Hsu E, James DF, Montserrat E. Changes in clinical stage identify patients with CLL and different outcome within iwCLL partial response: RESONATE study. Br J Haematol. 2019 Apr;185(1):148-150. Epub 2018 May 31.
Molica S, Giannarelli D, Montserrat E. Minimal Residual Disease and Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis. Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):423-430. Epub 2019 Mar 23.
Montserrat E, Gale RP. Predicting the outcome of patients with chronic lymphocytic leukemia: Progress and uncertainty. Cancer. 2019 Nov 1;125(21):3699-3705. Epub 2019 Aug 5.

2020

Bosch R, Mora A, Cuellar C, Ferrer G, Gorlatov S, Nomdedéu J, Montserrat E, Sierra J, Rai KR, Chiorazzi N, Moreno C. FcγRIIb-BCR Co-Ligation Inhibits BCR Signaling in Chronic Lymphocytic Leukemia. Haematologica. 2020 Mar 26. Epub 2021 Jan 1.
Molica S, Giannarelli D, Baumann T, Montserrat E. Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis. Eur J Haematol. 2020 May;104(5):512-515. Epub 2020 Feb 22.
Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoechstetter MA, Herling CD, De Paoli L, Delgado J, Rabe KG, Gentile M, Doubek M, Mauro FR, Chiodin G, Mattsson M, Bahlo J, Cutrona G, Kotaskova J, Deambrogi C, Ekström Smedby K, Spina V, Bruscaggin A, Wu W, Moia R, Bianchi E, Gerber B, Zucca E, Gillessen S, Ghielmini ME, Cavalli F, Stuessi G, Hess MA, Baumann TS, Neri A, Ferrarini M, Rosenquist R, Forconi F, Foa R, Pospisilova S, Morabito F, Stilgenbauer S, Döhner H, Parikh SA, Wierda WG, Montserrat E, Gaidano G, Hallek M, Rossi D. International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia. Blood. 2020 May 21;135(21):1859-1869.
Baumann T, Delgado J, Montserrat E. CLL and COVID-19 at the Hospital Clinic of Barcelona: An Interim Report. Leukemia. 2020 Jul;34(7):1954-1956. Epub 2020 May 19.
Rossi D, Shadman M, Condoluci A, Brown JR, Byrd JC, Gaidano G, Hallek M, Hillmen P, Mato A, Montserrat E, Ghia P. How we manage patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemic. Hemasphere. 2020 Jul 30;4(4):e432.
Molica S, Baumann TS, Lentini M, Levato L, Delgado J, Montserrat E. The BALL prognostic score identifies relapsed/refractory CLL patients who benefit the most from single-agent ibrutinib therapy. Leuk Res. 2020 Aug;95:106401. Epub 2020 Jun 10.
Rovira M, Villamor N, Cobo F, Fernández-Aviles F, López-Guerra ML, Guijarro F, Baumann T, Montserrat E. Is chronic lymphocytic leukemia curable? A clinical case relapsing 21 years after allogeneic stem-cell transplantation. Bone Marrow Transplant. 2020 Sep;55(9):1860-1861. Epub 2020 Mar 20.
Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, Garcia-Marco JA, Hernández-Rivas JÁ, Mirás F, Baile M, Marquet J, Niemann CU, Reda G, Munir T, Gimeno E, Marchetti M, Quaglia FM, Varettoni M, Delgado J, Iyengar S, Janssens A, Marasca R, Ferrari A, Cuéllar-García C, Itchaki G, Špaček M, De Paoli L, Laurenti L, Levin MD, Lista E, Mauro FR, Šimkovič M, Van Der Spek E, Vandenberghe E, Trentin L, Wasik-Szczepanek E, Ruchlemer R, Bron D, De Paolis MR, Del Poeta G, Farina L, Foglietta M, Gentile M, Herishanu Y, Herold T, Jaksic O, Kater AP, Kersting S, Malerba L, Orsucci L, Popov VM, Sportoletti P, Yassin M, Pocali B, Barna G, Chiarenza A, Dos Santos G, Nikitin E, Andres M, Dimou M, Doubek M, Enrico A, Hakobyan Y, Kalashnikova O, Ortiz Pareja M, Papaioannou M, Rossi D, Shah N, Shrestha A, Stanca O, Stavroyianni N, Strugov V, Tam C, Zdrenghea M, Coscia M, Stamatopoulos K, Rossi G, Rambaldi A, Montserrat E, Foà R, Cuneo A, Ghia P. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020 Sep;34(9):2354-2363. Epub 2020 Jul 9.
Montserrat E. When CLL meets COVID-19. Blood. 2020 Sep 3;136(10):1115-1116.
Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, Gregor M, Cymbalista F, Buske C, Hillmen P, Hallek M, Mey U; ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Oct 19:S0923-7534(20)42469-X. Epub 2021 Jan.

2021

Baumann T, Moia R, Gaidano G, Delgado J, Condoluci A, Villamor N, Payedimarri AB, Costa D, Patriarca A, Jiménez-Vicente C, Rossi D, Montserrat E. Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients. Leukemia. 2021 Aug;35(8):2325-2331.2021. Epub 2021 Feb 4.
Molica S, Giannarelli D, Montserrat E. Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis. Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):216-223. Epub 2020 Oct 29.